

1 Combining machine learning and mathematical models of disease dynamics to 2 guide development of novel disease interventions

3
4 **Authors:** Monica Golumbeanu^{1,2,†}, Guojing Yang^{1,2,†}, Flavia Camponovo^{1,2,3}, Erin M. Stuckey⁴,
5 Nicholas Hamon⁵, Mathias Mondy⁵, Sarah Rees⁵, Nakul Chitnis^{1,2}, Ewan Cameron^{6,7,8}, and
6 Melissa A. Penny^{1,2,*}

7 **Affiliations:**

8 ¹Swiss Tropical and Public Health Institute, Basel, Switzerland

9 ²University of Basel, Basel, Switzerland

10 ³Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H.
11 Chan School of Public Health, Boston, MA 02115, USA

12 ⁴The Bill and Melinda Gates Foundation, Seattle, WA, USA

13 ⁵Innovative Vector Control Consortium, Liverpool, United Kingdom

14 ⁶Malaria Atlas Project, Big Data Institute, University of Oxford, Oxford, UK

15 ⁷Curtin University, Perth, Australia

16 ⁸Telethon Kids Institute, Perth Children's Hospital, Perth, Australia

17 †These authors contributed equally.

18 **Email:** *Correspondence to: melissa.penny@unibas.ch

19
20 **One Sentence Summary:** Defining quantitative profiles of novel disease interventions by
21 combining machine learning with mathematical models of disease transmission

22 **Abstract:**

23 The development of novel interventions against a disease entails optimising their specifications
24 to achieve desired health goals such as disease reduction. As testing is limited early in
25 development, it is difficult to predefine these optimal specifications, prioritize or continue
26 investment in candidate interventions. Mathematical models of disease can provide quantitative
27 evidence as they can simulate deployment and predict impact of a new intervention considering
28 deployment, health-system, population and disease characteristics. However, due to large
29 uncertainty early in development, as well as model complexity, testing all possible combinations
30 of interventions and deployments becomes infeasible. As a result, mathematical models have
31 been only marginally used during intervention development to date. Here, we present a new
32 approach where machine learning enables the use of detailed disease models to identify optimal
33 properties of candidate interventions to reach a desired health goal and guide development. We
34 demonstrate the power of our approach by application to five novel malaria interventions under
35 development. For various targeted reductions of malaria prevalence, we quantify and rank
36 intervention characteristics which are key determinants of health impact. Furthermore, we
37 identify minimal requirements and tradeoffs between operational factors, intervention efficacy
38 and duration to achieve different levels of impact and show how these vary across disease
39 transmission settings. When single interventions cannot achieve significant impact, our method
40 allows finding optimal combinations of interventions fulfilling the desired health goals. By
41 enabling efficient use of disease models, our approach supports decision-making and resource
42 investment in the development of new interventions for infectious diseases.

44 **Significance Statement**

45 During development of novel disease interventions (e.g. vaccines), a target product profile (TPP)
46 document defines intervention characteristics required to meet health goals. As clinical trials are
47 limited early in development, mathematical models simulating disease dynamics can help define
48 TPPs. However, testing all combinations of intervention, delivery and environment
49 characteristics is infeasible and so complex mathematical models have not been used until now.
50 We introduce a new approach to define TPPs, combining models of disease with machine
51 learning. We examined several novel malaria interventions, identifying key characteristics,
52 minimum efficacy and duration of effect that ensure significant reductions in malaria prevalence.
53 This approach therefore enabled mathematical models of disease to support intervention
54 development, by identifying intervention requirements that ensure public health impact.

55 **Introduction**

56 Target Product Profiles (TPPs) are dynamic documents commonly used during the development
57 of a cutting-edge medical product, defining its required characteristics to fulfill an unmet health
58 need (1). By offering a comprehensive snapshot of the development process at any given point in
59 time, a TPP constitutes a vital reference for dialogue between various stakeholders to guide
60 decisions on the development direction to be pursued (1-5). A well-constructed TPP is thus
61 essential for efficient resource allocation and success during the development phase (1, 5).
62 However, the process of establishing TPPs relies on minimal clinical or quantitative evidence.
63 They are often set by expert opinion and consensus based on limited quantitative consideration
64 of the complex dynamics of disease or predictions of the likely intervention impact while
65 achieving the identified unmet health need (6). Furthermore, few TPPs consider operational
66 aspects such as deployment coverage in addition to product-specific characteristics such as
67 efficacy or half-life. This has implications for the appropriate definition of intervention
68 effectiveness characteristics according to local health systems and health targets (1, 6, 7).

69 Mathematical models of disease transmission dynamics can be used to bridge this gap, as they
70 quantitatively estimate the impact of interventions while including considerable evidence of
71 disease progression and transmission, host immunity, as well as environmental or health system
72 dynamics and their interaction with interventions (8, 9) (Fig. 1). However, models have been
73 mainly used at late stages during the development of a new intervention; for example, to predict
74 likely impact or cost-effectiveness from data collected in Phase 3 clinical trials (10-15). Model
75 investigations are usually informed by scenario analysis accounting for the delivery and target
76 age groups, as well as properties of the new intervention pre-defined or informed by late clinical
77 trials (16-19). In these constrained scenarios, high model and parameter complexity tend to
78 obscure the complex relationships between intervention parameters, operational factors, health
79 outcomes and public health impact (20). Exhaustive scenario analyses are highly
80 computationally expensive, rendering the full exploration of all possible interventions for a
81 disease, in conjunction with all possible delivery scenarios, combinatorically infeasible.

82 Here we propose a new ethos where epidemiological models guide the development of novel
83 disease interventions designed to achieve quantified health goals. To do this efficiently, we use

84 machine learning combined with mathematical models to perform a directed search of the entire
85 space of intervention profiles, to define properties of new interventions (sometimes referred to as
86 “tools” or “products”) that will achieve the desired health goal. Placing the end goal of public
87 health impact at the center of decision making is increasingly important to direct Research &
88 Development (R&D) efforts in the face of finite resources. The use of mathematical models
89 enables translation of R&D efforts into potential impact. In this paper, we show how modelling
90 can support this process, and introduce a framework that quantitatively defines product
91 characteristics within TPPs.


92 Previous approaches using disease models to inform TPPs have tackled the combinatorically-
93 complex parameter space by only exploring a discrete, constrained set of parameters (21-23).
94 These approaches have provided insightful knowledge and emphasized the importance of using
95 disease models for defining TPPs. Nevertheless, they have provided a concomitantly constrained
96 view of intervention specifications. Our framework tackles and moves beyond these challenges.
97 On one hand, it allows us to rigorously define TPPs by efficiently exploring highly complex
98 parameter spaces of mathematical disease models, and on the other hand it identifies the
99 determinants of desired public health impact to inform tradeoffs between product characteristics
100 and use-cases. Furthermore, as the ultimate health goal guides decisions on interventions and for
101 optimal use of the supportive framework presented here, an engaging, iterative exchange with
102 stakeholders to define desired outcomes and the likely delivery use-cases of the new
103 interventions is essential.

104 Our framework utilizes a machine learning approach using Gaussian processes (GPs) (24) to
105 generate computationally light emulators of detailed mathematical models of disease dynamics
106 (Fig. 2A). These emulators constitute an interface that easily links properties of deployed
107 interventions and operational factors to health goals. Furthermore, the emulators capture not just
108 the mean tendency of complex disease models dynamics, but also the inherent variance caused
109 by the stochasticity in the models (25). Disease model emulators allowed us to efficiently
110 perform sensitivity analyses of intervention and health system parameters on predicted public
111 health impacts at low computational cost. Furthermore, by coupling emulators with nonlinear
112 optimization techniques, we constructed a predictive framework that identifies key determinants
113 of intervention impact as well as the minimal intervention profiles required for achieving a given

114 health goal (Fig. 2). The framework consists of (i) a comprehensive disease progression and
115 transmission simulation model applied on a discrete, uniformly sampled set of input parameters;
116 (ii) training of an emulator on the sampled set of parameters and corresponding impact
117 outcomes; (iii) using sensitivity analysis to understand drivers of intervention impact; and (iv)
118 applying a non-linear constrained optimization algorithm to explore intervention operational and
119 effectiveness characteristics meeting various targets and deployment use-cases specified
120 following iterative consultation with product development experts. A detailed description of the
121 components of the developed framework can be found in Fig. 2A and the Materials and Methods
122 section.

123 We apply our framework to assess and optimize new interventions for preventing malaria
124 transmission. Strategic investment in new interventions is becoming crucial for malaria control
125 and elimination programs, as existing interventions are currently challenged by increasing
126 resistance (26-28). Mathematical models of malaria transmission (Fig. 1) have been used
127 extensively to estimate the impact of malaria interventions and to optimize intervention packages
128 for specific geographies (10, 29-32). As yet, these malaria models have not been systematically
129 applied in directing the design of new interventions, nor in understanding how intervention-
130 specific, epidemiological and systems factors jointly contribute to impact. Following
131 consultation with malaria product development experts, we used our new framework to define
132 the required profiles in terms of coverage, efficacy and duration characteristics in TPPs of new
133 putative malaria interventions to reach desired public health goals such as prevalence reduction
134 contingent on operational constraints (Fig. 2).

135



136

137

138 **Fig. 1 Schematic of a stochastic simulation platform of malaria transmission dynamics.**

139 *OpenMalaria* (33) is an open source, stochastic, individual-based model which simulates
 140 malaria epidemiology and transmission dynamics across humans and mosquitoes. The pattern of
 141 yearly malaria infection in the absence of interventions is determined by the entomological
 142 inoculation rate (EIR), which is a model input. Each infected human host in the simulated
 143 population has an associated parasite density and duration of infection, where each infection is
 144 also modelled individually, and follows a modelled transmission cycle (central diagram) which
 145 captures effects such as immunity, infectiousness to mosquitoes, morbidity or mortality. During
 146 the simulation, a wide range of human and vector interventions can be applied, affecting the
 147 transmission cycle at various stages (red arrows). Setting-specific characteristics such as
 148 population demographics, mosquito species entomological characteristics or seasonality are
 149 explicitly modelled. Various health outcomes are monitored over time including patent
 150 infections, uncomplicated clinical disease, severe disease in and out of hospital and malaria
 151 mortality (a detailed description of the simulation model and its features is provided in *Materials*
 152 *and Methods* and *Table S1.1*).

153

154 **Results**

155 *A disease model and machine learning approach to quantitatively define malaria interventions*


156 Our analysis workflow (Fig. 2) starts with sensibly-informed TPP scenarios; the definition of
157 targeted health goals corresponding to unmet health needs; and possible use cases following
158 continuous consultation with product development experts. The health goals in the present
159 analysis are reductions of malaria prevalence for all ages ($PfPR_{0-99}$) and prevention of
160 resurgence. Next, within the “*Disease model*” component, malaria transmission is modeled by
161 the means of the established, stochastic, individual-based model OpenMalaria (33) (Fig. 1, Table
162 S1.1). A comprehensive set of simulated scenarios is built by uniformly sampling the parameter
163 space (defined by the parameters emphasized in bold under “*Tool specifications*” and “*Setting*”
164 components in Fig. 2 and detailed in Table S2.1). The scenarios are simulated with the disease
165 model yielding an extensive database of disease outcomes. In the machine learning part of the
166 approach, the database of simulated scenarios and corresponding outcomes is used to train a
167 predictive model, in this case a Heteroskedastic Gaussian process model (see detailed training
168 procedure in Materials and Methods). The predictive model acts as an emulator of the complex
169 individual-based mathematical model. Specifically, the emulator can predict the disease outcome
170 for the given health goal and any set of input parameters. For this reason, the trained emulator
171 can be efficiently and promptly used in downstream analyses to design TPPs of new malaria
172 interventions, and to identify their quantitative properties to meet the health goal previously
173 defined. More precisely, sensitivity analysis allows searching for key determinants of
174 intervention impact, while constrained optimization analyses yield the optimal required
175 intervention properties that meet specified impactful health goals.

176 We used our validated individual-based model, “OpenMalaria” (29, 33) (detailed description in
177 the Materials and Methods section, Fig. 1 and Table S1.1) to simulate malaria epidemiology and
178 transmission dynamics within various transmission settings. These settings cover a broad
179 spectrum of transmission and mosquito biting behavior archetypes relevant for attaining general
180 guiding principles in the early development phase of new interventions. Within the simulations,
181 we quantitatively examined several malaria interventions that are currently under development or
182 developed within the last ten years, including monoclonal antibodies, drugs, vaccines as well as
183 novel vector control interventions. To be able to investigate a wide range of interventions,

184 instead of considering their characteristics explicitly, we more generally modelled their action on
185 parasite or vector targets (Fig. 1). Accordingly, each intervention was modeled through its
186 deployment coverage, efficacy, half-life or duration of effect on the given parasite or vector stage
187 in the transmission cycle (see Materials and Methods, Fig. S2.3, Table S2.1 for detailed
188 intervention specifications). For simplification, the words ‘half-life and ‘duration’ are used
189 interchangeably to describe the longevity of the intervention effect (further details and
190 definitions in Materials and Methods).

191 Intervention impact in the current study was assessed assuming a single health goal of malaria
192 prevalence reduction and thus through predicted reduction in *Plasmodium falciparum* malaria
193 prevalence across all ages, $PfPR_{0-99}$, corresponding to true infection prevalence and not patent
194 (detected with a diagnostic such as rapid diagnostic test (RDT), or polymerase chain reaction
195 (PCR), Fig. S2.2, S3.1-S3.4). We learned simplified predictive emulators for the OpenMalaria
196 simulation results by training GP models on a limited set of simulated scenarios (Fig. 2B). We
197 show that the trained GP models accurately capture the dependencies between the disease model
198 input parameters and the output intervention impact, and are able to reliably predict the reduction
199 in $PfPR_{0-99}$ attributable to any input intervention characteristics (Fig. 2B, S4.1-S4.3, Table S4.1).
200 Our work thus builds on recent applications of GPs in disease modelling and burden prediction
201 for malaria (34). Using the trained GP emulator, through global sensitivity analysis, we evaluated
202 the key determinants of intervention impact (Fig. 2C). In addition, we performed a constrained
203 search for intervention and delivery profiles (TPPs) that maximize impact under a particular
204 health goal, given concrete, expert-informed, operational constraints such as possible
205 deployment coverage, or feasible intervention properties such as efficacy or duration of
206 protection (Fig. 2D).

207



208

209 **Fig. 2 Quantitatively defining TPPs of novel disease interventions.**
 210 (A) Detailed schematic representation of the proposed quantitative framework to support
 211 product development (full specifications in Materials and Methods). Figures (B)-(D) present the
 212 results of applying the framework for an anti-infective malaria vaccine (mass administration,
 213 seasonal transmission with high indoor mosquito biting): (B) Correlation between simulated
 214 true (x axis) and emulator predicted (y axis) PfPR_{0.99} reduction with a GP emulator trained in a
 215 cross-validation scheme (Pearson correlation coefficient r^2 distribution shown in boxplot) and
 216 validated on an out-of-sample test set (r^2 left upper corner and grey diamond on the boxplot in
 217 the right lower corner). (C) Example vaccine impact determinants: the colors represent
 218 proportions of the emulator output variance (relative importance) attributable to intervention
 219 specifications, as well as health system access. (D) Example feasible landscape of optimal
 220 vaccine efficacy profiles for various health goals (minimum targeted PfPR_{0.99} reductions, y axis).
 221 For each health goal, the heatmap displays the minimum required efficacy when applied at a
 222 coverage of 60% and with a half-life of 7 months, assuming an access to care level of 25%
 223 (example in the insert plot for a target reduction of at least 60%). Results in figures (C) and (D)
 224 are displayed for a range of median simulated true PfPR₂₋₁₀ (before intervention deployment,
 225 rounded values, x axis).

226


227 *Intervention impact and the importance of their characteristics*

228 With guidance from different groups of experts and partners (see definition of the various
229 stakeholders involved in Materials and Methods), we conducted an extensive analysis in the
230 malaria development space, covering a diverse spectrum of interventions pertaining to 1) anti-
231 infective monoclonal antibodies 2) anti-infective vaccines, 3) transmission-blocking vaccines, 4)
232 outdoor attractive targeted sugar baits, and 5) eave tubes. Following simulation with
233 OpenMalaria of deployment of each of these interventions through mass administration
234 campaigns over several years (see Materials and Methods), we first analyzed the predicted
235 distributions of reduction in true $PfPR_{0-99}$ (Fig. 3A, S3.2-S3.4). We found that, in general, when
236 aiming for substantial, prompt reductions in prevalence for this particular health target, vector
237 control was by far the most impactful intervention across all settings. Monoclonal antibodies,
238 anti-infective and transmission-blocking vaccines had a more pronounced impact in low-
239 transmission settings compared to endemic settings (Fig. 3A, S3.1-S3.4, Table S5.1).

240 Sensitivity analysis indicated that the impacts of these interventions on malaria prevalence were
241 driven by different characteristics of their efficacy profiles, deployment strategies, or access to
242 care for treatment of clinical cases, for either short and long impact follow-up (Fig. 3B-E, S6.1 –
243 6.2). Across a large proportion of the simulated scenarios, over all parasite and vector targets and
244 interventions, coverage of the deployed intervention was overwhelmingly the primary driver of
245 impact especially in low transmission settings (Fig. 3B-E, S6.1-S6.2). For therapeutic
246 interventions, the impact of short-term passive immunizations such as monoclonal antibodies
247 relied on their deployment coverage and the health system (Fig. 3B, S6.1). In contrast, for long-
248 acting interventions such as vaccines, impact was driven by deployment coverage and efficacy
249 (Fig. 3C, S6.1). Highly-efficient vector control interventions such as attractive targeted sugar
250 baits had a strong effect on prevalence (Fig. 3A), and their duration of effect was the most
251 important determinant (Fig. 3D, S6.2). The immediate impact of long-term vector control
252 interventions such as eave tubes was driven by deployment coverage, while their half-life was a
253 key determinant for preventing resurgence (Fig. 3E, S6.2).

254

255



256

257 **Fig. 3: Effects of novel malaria interventions on disease prevalence and their key drivers of**
 258 **impact.**


259 (A) Distribution of obtained reduction in $PfPR_{0-99}$ following deployment of various malaria
 260 interventions under development (shown with different colors) for a range of simulated
 261 transmission settings (specified by median true $PfPR_{2-10}$ rounded values, x axis). Each boxplot
 262 displays the interquartile range (box), the median value (horizontal line), the largest and
 263 smallest values within 1.5 times the interquartile range (whiskers), and the remaining outside
 264 values (points) of the $PfPR_{0-99}$ reduction values obtained across all the simulations for each
 265 given setting. The remaining plots of the figure present the results of sensitivity analysis showing,
 266 across the same simulated $PfPR_{2-10}$ settings, the determinants of intervention impact on $PfPR_{0-99}$
 267 reduction for anti-infective monoclonal antibodies (B), transmission-blocking vaccines (C),
 268 attractive targeted sugar baits (D) and eave tubes (E). Determinants of impact are shown for
 269 both immediate and late follow-up, when interventions are applied once per year for three years
 270 in a seasonal transmission setting with high indoor mosquito biting (full intervention
 271 specifications provided in Materials and Methods and results for other settings and interventions
 272 shown in Fig. S6.1-6.2 and Table S5.1).

273

274 *Minimal requirements of novel malaria interventions to achieve a defined health goal*

275 For the five aforementioned malaria interventions, we explored their optimal profiles for a broad
276 set of target $PfPR_{0-99}$ reduction levels, creating landscapes of intervention profiles according to
277 their minimal characteristics across various transmission settings (Fig. 4-5, S7.1-S8.5). These
278 landscapes provide a broad and comprehensive overview of the intervention potential
279 capabilities and limitations in achieving a desired health goal. For example, as opposed to an
280 anti-infective monoclonal antibody which requires high efficacy and duration to achieve large
281 $PfPR_{0-99}$ reduction in only a limited number of settings (Fig. 4A-B, S7.1-S7.2), attractive targeted
282 sugar baits that kill mosquitoes achieve a wider range of target $PfPR_{0-99}$ reductions in high-
283 transmission settings as well (Fig. 4C-D, S7.5). Similarly, while in settings with lower
284 transmission ($PfPR_{2-5} < 30\%$), anti-infective and transmission-blocking vaccines had comparable
285 requirements in achieving similar $PfPR_{0-99}$ reduction targets, anti-infective vaccines showed a
286 higher potential and reached additional targets in high-transmission, endemic settings (Fig. 5).

287



288

289 **Fig. 4: Estimated optimal intervention and delivery profiles (TPPs) for monoclonal**
 290 **antibodies and attractive targeted sugar baits.**

291 *The heatmaps in figures (A) and (C) represent landscapes of optimal, constrained intervention*
 292 *specifications (coverage, efficacy, and half-life) required to achieve a broad range of targeted*
 293 *minimal reductions in PfPR₀₋₉₉ (y axis) across different simulated true PfPR₂₋₁₀ settings (rounded*
 294 *values, x axis). Each intervention characteristic was minimized in turn, while keeping the other*
 295 *characteristics fixed (values marked on each figure). Results are shown for an anti-infective*
 296 *monoclonal antibody (A) and attractive targeted sugar baits (C). For a defined health goal of*
 297 *reduction in PfPR₀₋₉₉ (dashed horizontal lines on figures (A) and (C)), the corresponding*
 298 *minimum product profile requirements are shown for an anti-infective monoclonal antibody in*
 299 *(B) and attractive targeted sugar baits in (D). Both figures (B) and (D) show how these*
 300 *requirements change when these interventions are delivered at various frequencies (once or*
 301 *twice per year), and when the anti-infective monoclonal antibody is delivered in combination*
 302 *with a blood-stage drug. The simulated health system access was 25%. Descriptions of all*
 303 *intervention properties for identification of minimal profiles are detailed in Table S2.2, while*
 304 *additional results for other settings and interventions are provided in Fig. S7.1-S7.6 and Table*
 305 *S5.1.*

306

307 For a detailed overview of landscapes of intervention profiles for all simulated settings and
308 interventions see Fig. S7.1-S7.6. These landscapes together with the results of the sensitivity
309 analysis offer an evidence-based prioritization of resources during the product development
310 process. For example, we found that while both efficacy and half-life are important for
311 immediate prevalence reductions with monoclonal antibodies, their effect is limited in preventing
312 resurgence and is only supported by high case-management levels (Fig. 3, 4, S6.1, S7.1-S7.2).
313 Conversely, the efficacy of anti-infective vaccines drives immediate impact, whereas half-life of
314 effect has greater importance for achieving and maintaining $PfPR_{0-99}$ reductions (Fig. 3, 5, S6.1,
315 S7.3-S7.4). These results suggest that if vaccines and monoclonal antibodies are to support
316 preventing resurgence, then R&D efforts should focus on increasing and establishing antibody
317 longevity.

318 Our analysis shows that coverage is the primary driver of impact (Fig. 3B-E, S6.1-S6.2). This
319 result has important implications for interventions requiring multiple applications to achieve high
320 efficacy, indicating that it is of crucial importance to target both vulnerable populations and the
321 proportion of the population missed by the intervention. While for some interventions high
322 coverage deployment might be very difficult or impossible to achieve, our analysis shows that
323 this can be alleviated by increasing the deployment frequency or through deploying
324 combinations of interventions, which may have cost implications (Fig. 4B, 4D, 5B, 5D, S7.1-
325 S7.5, S8.1-8.4).

326 We found that combining several interventions targeting different stages in the transmission
327 cycle can strongly affect the minimum requirements of a putative new intervention, potentially
328 increasing the impact of an otherwise weaker intervention. For example, for an anti-infective
329 monoclonal antibody with an initial half-life of 7 months and deployed at a coverage of 60%
330 reflecting completion of multiple doses, achieving a prevalence reduction of 80% was impossible
331 when deployed once yearly for three years (Fig. 4A, S7.1). Furthermore, achieving the
332 aforementioned health goal required an efficacy of 80% when the intervention was deployed
333 twice per year for three years (Fig. 4B, Fig. S7.2). However, when deployment of the
334 monoclonal antibody was coupled with a short half-life blood-stage parasite treatment such as
335 dihydroartemisinin-piperazine or artemether-lumefantrine, its minimum required efficacy was
336 considerably reduced for both delivery frequencies (Fig. 4B, S7.1-S7.2, S8.1). Conversely, if we

337 assume an initial efficacy of 85% for the monoclonal antibody, we find that its minimal required
338 half-life can be reduced if we deploy this intervention in combination with the blood-stage
339 parasite clearing drug (Fig. 4B, S7.1-S7.2, S8.1). These results partly motivated the current
340 development of anti-infective monoclonal antibodies; use-cases will likely include deployment
341 with existing or new antimalarial treatment.

342 We also showed that a modified deployment schedule could reduce requirements for properties
343 of some interventions. For example, for highly-efficacious attractive targeted sugar baits, higher
344 coverage and half-life were required when implemented once per year for three years compared
345 with an accelerated delivery schedule of twice per year for three years (Fig. 4C-D). Except for
346 high transmission settings ($PfPR_{2-10} > 41\%$), a minimum required efficacy of 70% was sufficient
347 to attain the desired health goal for the majority of settings and for both delivery schedules (Fig.
348 4C-D, Fig. S7.5, Fig. S8.4). This result is also reflected in the sensitivity analysis (Fig. 3D).
349 Accordingly, the variation in intervention efficacy in the ranges investigated has little importance
350 in driving the intervention impact and suggests that, once a vector control intervention such as
351 attractive targeted sugar baits achieves a high killing efficacy (here greater than 70%), a next step
352 of optimizing other intervention characteristics such as deployment coverage or duration leads to
353 a higher impact. These results demonstrate the strength of our analysis in identifying the
354 intervention characteristics to be prioritized for R&D.


355 When coupled with a short half-life blood-stage parasite treatment, requirements of coverage,
356 efficacy and half-life were reduced also for anti-infective and transmission blocking vaccines to
357 achieve the targeted reductions of $PfPR_{0-99}$ (Fig. 5, S7.3-7.4, S8.2-S8.3). In particular for high-
358 transmission settings ($PfPR_{2-5} > 25\%$), given an RTS,S-like half-life of 7 months, both anti-
359 infective and transmission-blocking vaccines could not achieve any of the defined prevalence
360 reduction goals if deployed singly. This was the case for any deployment coverage given an
361 initial efficacy of 85% as well as for any efficacy given a deployment coverage of 60%.

362 Combining vaccine deployment with a blood-stage drug not only significantly expanded the
363 achievable health targets also to high-transmission settings, but also reduced vaccine properties
364 requirements. Our analysis reveals that anti-infective vaccines had a higher potential than
365 transmission-blocking vaccines, requiring less performance and achieving higher prevalence
366 reductions targets also in higher transmission settings. When combined with blood-stage parasite

367 treatment, the coverage, efficacy and half-life requirements of anti-infective vaccines were lower
368 compared to those of transmission-blocking vaccines for the same prevalence reduction targets
369 (Fig. 5, S7.3, S7.4, S8.2, S8.3).

370 Our comprehensive analysis was applied to explore determinants of impact and required profiles
371 of interventions across two seasonal settings (seasonal and perennial) and three types of
372 mosquito biting patterns (low, medium and high indoor biting). A detailed overview of impact
373 determinants and optimal intervention profiles is presented in the Supplementary Materials (Fig.
374 S6.1-S8.5, and additional key results summarized in Table S5.1).

375



376

377 **Fig. 5. Estimated optimal intervention and delivery profiles (TPPs) for anti-infective and**
 378 **transmission blocking vaccines deployed once per year with or without a blood stage**
 379 **clearing drug.**

380 *The heatmaps in figures (A) and (C) represent landscapes of optimal, constrained intervention*
 381 *characteristic profiles (coverage, efficacy, and half-life) required to achieve various health goals*
 382 *(quantified by minimal reduction in $PfPR_{0-99}$, y axis) across different simulated true $PfPR_{2-10}$*
 383 *settings (rounded values, x axis). Each intervention characteristic was minimized in turn, while*
 384 *keeping the other characteristics fixed (values marked on each figure). Results are shown for an*
 385 *anti-infective vaccine (A) and a transmission blocking vaccine (C). Given a defined health goal*
 386 *of reduction in $PfPR_{0-99}$ (minimum 70% reduction, dashed horizontal lines on figures (A) and*
 387 *(C)), the corresponding minimum product profile requirements are shown for the same two*
 388 *interventions, i.e., for an anti-infective vaccine in (B) and transmission blocking vaccine in (D).*
 389 *Both figures (B) and (D) show how the minimum required profiles change when these*
 390 *interventions are delivered in combination with a blood-stage drug. The simulated case*
 391 *management level (E_5) for all the displayed optimization analyses was assumed 25%. The*
 392 *descriptions of all intervention properties for identification of minimal profiles are detailed in*
 393 *Table S2.2.*

394

395

396 Discussion

397 In this study, we introduced a new modeling and machine-learning framework that for the first
398 time enables quantitative differentiation between operational, setting, and intervention
399 parameters as determinants of intervention impact, using detailed simulation models of disease.
400 Our framework can be used for any disease where a valid model of disease progression or natural
401 history of disease is available. We provided mathematical tools for efficiently and quantitatively
402 defining the minimum profiles of malaria interventions as well as delivery approaches required
403 to reach a desired health goal. Furthermore, our methodology provides a means to refine the
404 identified optimal efficacy and duration characteristics as additional information becomes
405 available. As a result, we can apply fully-detailed disease models to direct the design of novel
406 interventions and understand how intervention-specific, epidemiological and systems factors
407 jointly contribute to impact and thus inform TPP guidance. Most immediately, the approach is
408 highly relevant to define successful interventions against emerging diseases such as SARS-CoV-
409 2, and to support efficient, fast development of operational strategies. As uncertainties in disease
410 progression and epidemiology can be incorporated in our approach, it also provides a way to
411 systematically sort through large complex landscapes of unknowns and thus refine properties of
412 interventions or clinical trials as more knowledge is available.

413 The value of our approach is realized through iterative collaboration with product development
414 experts, to perform model-based guidance throughout the development process, and refine
415 feedback on model predictions as interventions progress through development. For malaria,
416 where multiple interventions are in development, it also offers an approach for product
417 developers from diverse fields (such as therapeutics and insecticide development) to collaborate
418 and incorporate knowledge of other interventions into their TPP development. Although in our
419 analysis we used reduction of $PfPR_{0-99}$ as a health goal, our method can be applied to other
420 disease burden statistics as required. The same rationale applies for investigation of other
421 deployment strategies, required doses of interventions or further intervention combinations.

422 While also bringing valuable quantitative insights to guide product development, our analysis of
423 novel malaria interventions reproduces previous findings concerning intervention characteristics
424 which are key drivers of impact. Previous studies have shown that intervention coverage is a
425 major determinant of impact in the context of mass drug administration (17), of vaccines (35) as

426 well as vector control (36). Furthermore, our analysis reaffirms previous work showing the
427 ability of vector control interventions to achieve substantial reductions in malaria burden (37).

428 Our approach constitutes a powerful tool to help address the challenges of current malaria
429 strategies and develop new interventions to progress towards malaria elimination. While
430 currently promising interventions such as insecticide treated nets, seasonal malaria
431 chemoprevention (SMC) and intermittent preventative treatment (IPT) have been very successful
432 at reducing malaria incidence and saving lives, their improved burden reduction and future
433 success is currently challenged by limited adherence, resource and time constraints to increase
434 coverage and usage in underserved populations, as well as resistance (38). Furthermore, for
435 settings where SMC has not been implemented or not recommended (for example in East Africa
436 or in perennial settings), there remains a gap in available interventions to protect vulnerable
437 populations who experience the highest burden of malaria. Similarly, for settings with outdoor
438 biting mosquitoes, the development and rollout of novel vector control interventions is needed.
439 New therapeutics and immune therapies suitable for seasonal delivery such as long-acting
440 injectables or monoclonal antibodies are currently being developed that may close one of these
441 gaps (39, 40). However, in order to efficiently make decisions on their development, guidance on
442 their key performance characteristics and definition of their TPP documents is needed from early
443 stages. Our quantitative framework can support the development of interventions from the
444 beginning by generating the evidence to inform and define evaluation criteria ensuring new
445 products meet relevant health targets, while considering how these products may affect disease
446 burden and epidemiology within a population. As we show here, this relies on iterative dialogue
447 with stakeholders, to first define health targets, simulated scenarios, achievable intervention
448 properties and operational settings. The modelling part of the framework incorporates all this
449 information as well as relevant disease transmission dynamics, building an *in-silico* system for
450 testing the developed intervention. Next, the sensitivity analysis part of the framework informs
451 which intervention characteristics drive impact and are thus crucial in achieving the defined
452 health goal, providing insights on the development processes to be prioritized. Finally, the
453 optimization analysis part of the framework reveals the potential of the developed intervention
454 and how its efficacy and coverage requirements change according to the defined health targets
455 and deployment setting. The landscapes of intervention profiles help product developers to gauge
456 development and investment efforts and select promising products. Furthermore, our approach

457 allows investigating combinations of new and existing interventions, identifying alternatives to
458 alleviate shortcomings such as coverage limitations. To achieve a final TPP, several iterations of
459 the analysis are required, to ensure that the optimal tradeoffs between intervention capabilities
460 and target goals for a given setting are achieved.

461 As with all modelling studies, our approach is exposed to several limitations. The provided
462 quantitative estimations in this study incorporate an increased level of uncertainty due to the
463 additional emulation layer and are dependent on the performance of the trained emulator. We
464 addressed this challenge with extensive adaptive sampling and testing to ensure a high level of
465 accuracy of the trained emulators (Fig. 2, S4.1-S4.3, Table S4.1). Despite the intrinsic
466 uncertainty, the framework is intended to provide guiding principles and an efficient means of
467 exploring the space of intervention characteristics which otherwise would not be possible.
468 Evidently, our analysis relies on the disease model assumptions of disease and transmission
469 dynamics as well as expert opinion of likely intervention parameterizations in absence of clinical
470 knowledge. Lastly, the current analysis explored a subset of use-cases, transmission settings and
471 intervention combinations. Future work should focus on the likely settings and relevant use cases
472 as the interventions are being developed and their TPP documents refined.

473 Moving beyond the work presented in this paper, our framework would allow combining
474 simulation models with other sources of data describing geographical variation in disease, for
475 example, modelled health systems or modelled prevalence (41, 42) and to incorporate
476 interactions of interventions with novel interventions for surveillance. Clinical trials for new
477 interventions could thereby be prioritized to geographical settings, where public health impact is
478 likely to be maximized and where appropriate, to inform decisions on achieving non-inferiority
479 or superiority endpoints (43, 44). A significant extension is incorporating economic
480 considerations which may affect development decisions, including both costs of R&D, as well as
481 implementation and systems costs for final deployment.

482

483 **Materials and Methods**

484 The approach introduced here combines infectious disease modeling with machine learning
485 to understand determinants and define quantitative properties of target product profiles of new

486 malaria interventions. The building blocks and methodology of the approach are schematically
487 outlined in Fig. 2 which guides the following sections of Materials and Methods.

488 **1 Description of the disease model**

489 **1.1 Individual-based model of malaria transmission**

490 We used OpenMalaria (33, 45), an open source stochastic individual-based model to
491 simulate malaria epidemiology and transmission dynamics across humans and mosquitoes in
492 various settings. OpenMalaria considers the natural history of malaria in humans linked with a
493 deterministic, entomological model of the mosquito oviposition cycle and malaria transmission
494 in mosquitoes (46, 47) (Table S1.1). The modelled transmission cycle (Fig. 1) considers the
495 chain of processes following infection of a human host, simulating malaria infection in
496 individuals and modelling infection characteristics such as parasite density, duration of infection,
497 infectivity to mosquitoes, and health outcomes such as morbidity, mortality or anemia.
498 OpenMalaria specifically captures heterogeneity in host exposure, susceptibility and immune
499 response, taking into consideration the effects of several factors such as acquired immunity,
500 human demography structure, or seasonality (48-51). Furthermore, the model includes a detailed
501 representation of the health system (52), and of a wide range of human and vector control
502 interventions while tracking multiple health outcomes over time (Fig. 1, Table S1.1).

503 OpenMalaria has been widely documented and validated against a multitude of field
504 studies, compared to existing models and used in extensive studies to provide evidence for the
505 epidemiological effects of various interventions(10, 29, 33, 53-55). It comprises 14 model
506 variants based on distinct sets of assumptions on its epidemiology and transmission components
507 (45). For the present analysis, the “base” simulation model was used. The mathematical
508 equations of the model, its assumptions and calibrations have been thoroughly described in
509 numerous previous publications, therefore are not specified here, however, an overview of the
510 OpenMalaria modelled processes and assumptions along with the corresponding references are
511 provided in Table S1.1.

512

513 **1.2 Calibration of the disease model and description of simulation experiments**

514 OpenMalaria has been calibrated and validated in previous studies using historical
515 epidemiological data (29, 33, 45). The present analysis uses a previously-calibrated version of

516 the model which reflects demographics, epidemiology, entomology, health system and
517 seasonality of a health facility catchment area in Tanzania (50, 52, 56).

518 The simulated human population size in this analysis was 10'000 individuals, with its age
519 structure informed by data collected from a health and demographic surveillance site in Ifakara,
520 Tanzania, available through the INDEPTH network (57). For all simulations, we assumed there
521 were no imported infections during the whole study period.

522 Health system characteristics (Table S1.1) were defined through parameterization of a case
523 management model based on data provided by the Tanzanian National Malaria Control Program
524 (52). To define the simulated case management level, the probability of effective cure within two
525 weeks from the onset of fever (E_{14}) was varied within the interval [0 - 0.8] corresponding to a
526 probability of seeking care (access to treatment) within 5 days from the onset of fever (E_5) within
527 the interval [0.04 - 0.5] (53). During the model simulations, the case management level was
528 constant over time.

529 Mosquito entomological parameters and seasonal exposure patterns were estimated from
530 field studies conducted in the Namawala and Michenga villages located nearby Ifakara in
531 Tanzania (58, 59). Two archetypal seasonal settings were simulated: a seasonal exposure setting
532 with one transmission peak in September estimated from the mentioned field studies (Fig. S2.1),
533 and a perennial setting with uniform, constant exposure throughout the year. Two mosquito
534 species were present in the simulated settings: endophagic (indoor-biting, human blood index
535 equal to 0.99) and exophagic (outdoor-biting, human blood index is 0.5), respectively. The ratios
536 between the population sizes of indoor and outdoor mosquito species were classified into three
537 levels corresponding to high (indoor proportion is 0.8 out of total mosquito population), mid
538 (indoor proportion is 0.5) and low indoor biting (indoor proportion is 0.2). The extent of malaria
539 transmission in each simulation was defined by the yearly entomological inoculation rate (EIR).
540 For each simulation, EIR was sampled from the interval [1, 25] leading to a simulated range of
541 *Plasmodium falciparum* parasite rate or prevalence (*PfPR*) distributions across the various
542 transmission settings (Figures S2.1, S2.2, Table S2.1).

543

544 **1.3 Definition of intervention profiles**

545 Adopting a holistic view, we built an agnostic, standardized representation for each
546 malaria intervention. Accordingly, a malaria intervention was characterized through the targets

547 of the transmission life cycle it affects, along with the efficacy, half-life and decay of its effect
548 (Figure 1, S2.3, Table S2.1). The efficacy of a therapeutic intervention was quantified by its
549 ability to clear parasites or prevent infection, while for mosquito-targeted interventions (vector
550 control tools) it corresponded to the ability of the intervention to kill or prevent mosquitoes from
551 biting human hosts. For each intervention, its efficacy decayed over time according to a specific
552 decay type (defined in Fig. S2.3). The coverage of interventions was quantified by the
553 percentage of the population affected by the respective intervention. Geographical setting
554 characteristics such as entomological inoculation rates (EIR), seasonality, case-management
555 coverage, as well as transmission and vector characteristics were also included in the simulation
556 specifications (Fig. 1, Table S2.1).

557 We defined the following intervention targets in the transmission cycle (Fig. 1):

- 558 - **Anti-infective:** acts at the liver stage and prevents occurrence of a new infection
- 559 - **Blood stage clearance:** clears blood-stage parasites by administration of a drug
- 560 - **Transmission blocking:** prevents parasite development into gametocytes
- 561 - **Mosquito life-cycle killing effect:** kills mosquitoes during different stages of their life cycle,
562 such as, for example, before a blood meal (pre-prandial killing) and/or after a blood meal
563 (post-prandial killing). Furthermore, mosquitoes are affected by vector control interventions
564 according to their indoor and outdoor biting patterns.

565 The length of the intervention effect was described via either half-life for exponential,
566 sigmoidal or biphasic decay profiles, or by duration for step-like decay profiles. Generally, half-
567 life refers to half-life of intervention efficacy decay, representing the time in which the initial
568 intervention efficacy has been reduced by 50% (Fig. S2.3, Table S2.1). As opposed to half-life,
569 the duration of effect is equivalent to the entire decay time. For simplicity, since only one
570 intervention had a step-like decay, we use the words half-life and duration interchangeably.

571 To define the breadth, range and profiles of simulated malaria interventions, we
572 collaborated with end users at the Bill & Melinda Gates Foundation and the product development
573 partnerships PATH's Malaria Vaccine Initiative (PATH-MVI) and Innovative Vector Control
574 Consortium (IVCC). For each new intervention in the portfolio of PATH-MVI, IVCC and others,
575 we undertook several expert discussion groups to catalogue the ranges of potential effectiveness;
576 potential delivery strategies; parasite or vector targets; the likely properties in terms of action
577 (target), efficacy, duration and decay; and use cases/delivery (age target, mass intervention,

578 yearly deployment or other). These results are summarized in Table S2.1 which presents a
579 comprehensive description of all intervention characteristics, parameter values, as well as the
580 ranges they were varied within. Setting-specific characteristics used for the different simulated
581 scenarios are also summarized in Table S2.1.

582 In our current study, each intervention or combination of interventions was applied as
583 mass intervention targeting all ages equally, along with continuous case management. In this
584 analysis, we did not examine targeting particular populations or age groups to develop our
585 approach. The deployed mass intervention packages followed a long period of model warm up
586 (150 years), and were implemented in June and/or December for three years (Fig. S3.1).
587 Coverage at deployment time refers to the percentage of the population covered by the
588 intervention's initial efficacy, irrespective of how many doses/applications are required to reach
589 that coverage, assuming that the necessary doses have previously occurred.

590

591 **1.4 Translation of input EIR to $PfPR_{2-10}$ and $PfPR_{0-99}$**

592 For each simulation, OpenMalaria requires the definition of the intensity and seasonality
593 of malaria exposure specified through the input EIR level and its yearly profile in the absence of
594 interventions (Fig. S2.1). EIR is an appropriate measure for reflecting transmission intensity
595 (*60*), however it is difficult to measure in the field and its interpretation in the context of
596 intervention impact is difficult to apprehend when looking at the effects of drugs and vaccines
597 (*61, 62*). For this reason, although EIR is the force of infection input to all OpenMalaria
598 simulations, we report simulation outcomes and downstream analyses at the corresponding
599 median $PfPR_{2-10}$ and $PfPR_{0-99}$ before the interventions are deployed. We report true infection
600 prevalence and not patent PCR or RDT-detected. To do so, we discretized the continuous EIR
601 space into discrete unit-wide intervals and the median $PfPR$ was calculated across the obtained
602 $PfPR$ for all simulations in each discrete interval (Fig. S2.2).

603

604 **1.5 Definition of impact and health goals**

605 A comprehensive set of simulated scenarios was built by sampling uniformly the
606 parameter space of setting and intervention characteristics. To estimate the impact of the
607 deployed interventions, in each simulation, we calculated the reduction in $PfPR_{0-99}$ attributable to
608 the deployed intervention. $PfPR_{0-99}$ reduction was calculated by comparing the initial average

609 prevalence in the year before any interventions were deployed to the average yearly prevalence
610 obtained in the first year (short follow-up) and in the third year (long follow-up) after
611 deployment of interventions (Fig. S3.1). Consequently, the defined health goals corresponded to
612 a given minimum threshold of $PfPR_{0-99}$ reduction that the deployed interventions should achieve.

613 Figures S3.2 – S3.4 present the distributions of obtained $PfPR_{0-99}$ reduction for the
614 OpenMalaria simulation experiments covering all the interventions and deployments investigated
615 in the present study. In seasonal, low transmission settings ($EIR < 2$) a proportion of simulations
616 reached elimination before any intervention was deployed and were removed from the analysis
617 (Fig. S3.5). Since this happened for over 75% of simulations at $EIR < 2$, we did not investigate
618 optimal intervention profiles for transmission settings with $EIR < 2$. Arguably, for these settings
619 close to elimination, a different health goal, such as probability of elimination, would be more
620 appropriate which is not within the scope of the present study focusing on $PfPR_{0-99}$ reduction.

621

622 **2 Building a disease model emulator with Gaussian processes**

623 As it was computationally intensive and challenging to run an exhaustive number of
624 simulations in order to explore with OpenMalaria all the parameter space for diverse
625 combinations of interventions, settings and deployments, we applied machine learning
626 techniques and kernel methods to leverage our analysis. Precisely, starting from a training
627 dataset of simulations generated with OpenMalaria, we used Gaussian process (GP) models (24)
628 to infer the relationship between simulation variables (e.g., intervention coverage, half-life,
629 efficacy, etc.) and corresponding intervention impact ($PfPR_{0-99}$ reduction). This approach
630 allowed us to build a fast, simplified predictive model that could provide estimates of the disease
631 model output for any new inputs without running new OpenMalaria model simulations.

632 Gaussian process models are non-parametric models which define a prior probability
633 distribution over a collection of functions using a kernel, smooth function. Precisely, given the
634 relationship

$$y = f(\mathbf{x}) + \varepsilon$$

635 where y in our case is the $PfPR_{0-99}$ reduction and \mathbf{x} represents the set of intervention parameters
636 x_1, \dots, x_n , the main assumption of a GP is that

$$P(f(x_1), f(x_2), \dots, f(x_n)) \sim N(\mu, \Sigma)$$

637 where

$$\Sigma_{x_i, x_j} = K(x_i, x_j)$$

638 is the covariance matrix of the Gaussian distribution, μ is its mean and K is a kernel function
639 (24). Once data is observed, the posterior probability distribution of the functions consistent with
640 the observed data can be derived which is then used to infer outcomes at unobserved locations in
641 the parameter space (24). The intuition behind a GP model is based on the “smoothness”
642 relationship between its components. Accordingly, points which are close in the input parameter
643 space will lead to close points in the output space.

644

645 **2.1 Training data**

646 For each intervention and setting, a training dataset was built using discrete Latin hypercube
647 uniform sampling (63) across the input parameter space (defined in Table S2.1). Ten stochastic
648 realizations (replicates) of each sampled data point were considered. OpenMalaria was run on the
649 sampled data points and $PfPR_{0-99}$ was calculated for both short and long follow-up. The size of
650 the training set was varied between 10 and 1000 points (100 – 10000 including replicates) for
651 several simulation experiments (Fig. S4.1) and the performance of the trained GP was assessed
652 via the Pearson correlation coefficient r^2 . The minimum training set size which led to $r^2 > 0.95$
653 was selected for the remaining simulation experiments.

654

655 **2.2 Gaussian process emulators**

656 For each transmission setting and intervention, a GP model with a Gaussian kernel was
657 trained in a 5-fold cross-validation scheme using the training set with OpenMalaria simulations.
658 For training the GP, we used the R package *HetGP* version 1.1.1 (64, 65). *HetGP* is a powerful
659 implementation of GP models, featuring heteroskedastic GP modeling embedded in a fast and
660 efficient maximum-likelihood-based inference scheme.

661 GP performance was assessed by calculating the correlation between true and predicted
662 outputs on out-of-sample test sets as well as the mean squared error (Fig. S4.2 – 4.3, Table S4.1).
663 Precisely, the training set was split in 5 subsets and, iteratively, 4 of these subsets were used for
664 training the GP, while the remaining one was used as an out-of-sample test set during the cross-
665 validation procedure. After assessing the prediction error during the cross-validation procedure,
666 the GP was trained using the entire training set. Furthermore, since the trained GP model
667 provides the mean and variance of each predicted output, we used this probabilistic

668 representation to assess the uncertainty of the trained model across the entire parameter space
669 and to refine the GP model through adaptive sampling (66-68). Accordingly, we iteratively
670 sampled new training points from high-uncertainty regions of the parameter space and updated
671 the model with the new training samples until the correlation between true and predicted values
672 on an out-of-sample test set reached a plateau. Finally, a separate out-of-sample test set was built
673 to assess the overall performance of the GP (Fig. S4.2 – 4.3, Table S4.1).

674

675 **3 Identifying impact determinants through sensitivity analysis**

676 In order to estimate the contribution of each model input and its interactions with the
677 other inputs to the variance of the model outcome, we conducted a global sensitivity analysis
678 based on variance decomposition (69). This analysis shows which input parameters have higher
679 impact on the model outcome. It relies on the decomposition of the output variance in a sum of
680 individual input parameter conditional variances:

$$\text{Var}(Y) = \sum_i V_i + \sum_i \sum_{j>i} V_{ij} + \dots + V_{12\dots d}$$

681 where Y is the model outcome (in our case, $PfPR_{0-99}$ reduction), d corresponds to the number of
682 model inputs, and the conditional variances are defined as:

$$V_i = \text{Var}(E(Y|x_i))$$

$$V_{ij} = \text{Var}(E(Y|x_i, x_j)) - V_i - V_j$$

$$V_{ijk} = \text{Var}(E(Y|x_i, x_j, x_k)) - V_{ij} - V_{jk} - V_{ik} - V_i - V_j - V_k$$

683

...

684 with x_1, \dots, x_n representing the model input parameters.

685 Based on the above decomposition of output variance, the first order sensitivity index is defined
686 as:

$$S_i = \frac{V_i}{\text{Var}(Y)}$$

687 and corresponds to the proportion of output variance assigned to the main effect of X_i , i.e.,
688 regardless its interactions with other model inputs (69, 70).

689 To account for the contribution of each model input as well as the variance of its
690 interactions with other inputs to the variability of the model output, the total effect sensitivity
691 index is used:

$$T_i = 1 - \frac{\text{Var}(E(Y|x_{\sim i}))}{\text{Var}(Y)}$$

692 where the notation $\sim i$ stands for all indices except i (69, 70).

693 In the above decomposition of model output variance, by replacing the expressions of the
694 sensitivity indexes, the following properties can be deduced:

$$\sum_i S_i + \sum_i \sum_{j>i} S_{ij} + \dots + S_{12\dots d} = 1$$

695 and

$$\sum_i T_i \geq 1.$$

696 To compute the sensitivity indexes, we use the function “soboljansen” from the R
697 package “sensitivity” (71). The function estimates the sensitivity indices through MCMC
698 sampling, using a Monte Carlo approximation for computing conditional expectations. Within
699 the sampling scheme, we sampled 100’000 points to estimate the sensitivity indices.

700 Calculating the sensitivity indices defined above, the variance of the GP emulator output
701 was thus decomposed into proportions attributable to intervention characteristics, i.e.,
702 intervention efficacy, half-life and deployment coverage, as well as access to care. Using the
703 main effects, we defined the relative importance r_i of each characteristic as a proxy for impact
704 determinants as follows:

$$r_i = \frac{S_i}{\sum_{i=1}^d S_i}$$

705 where d is the number of intervention characteristics and $\sum_{i=1}^d r_i = 1$.

706 **4 Finding minimal intervention properties**

707 The trained GP models for each transmission setting and intervention were used within a
708 general-purpose optimization scheme in order to identify minimum intervention properties that
709 reach a defined $PfPR_{0-99}$ reduction goal given operational and intervention constraints.

710 Let

$$g(\mathbf{x}) = g(x_1, x_2, x_3, x_4)$$

711 denote the GP model predicting the mean prevalence reduction obtained after deploying an
712 intervention with given characteristics in a transmission setting, with

$$x_1 = \text{tool coverage}$$

$$x_2 = \text{tool half - life}$$

$$x_3 = \text{tool efficacy}$$

$$x_4 = \text{access to treatment.}$$

713 For various levels of $PfPR_{0-99}$ denoted with p_k , each intervention characteristic was
714 optimized separately, keeping the remaining characteristics as well as the level of case
715 management fixed to pre-set levels. Precisely, the optimization procedure searches for

$$\min(x_i) | x_{\sim i}$$

716 such as

$$g(\mathbf{x}) \geq p_k$$

717 with the constraints:

$$l_i \leq x_i \leq u_i,$$

718 where l_i and u_i are the lower and upper bounds of x_i , respectively and the notation $\sim i$ is used to
719 represent all the characteristics except i . A detailed description of the parameter specifications
720 during optimization for each intervention is provided in Table S2.2.

721 To solve the above optimization problem, we used a general nonlinear augmented
722 Lagrange multiplier method (72, 73) implemented in the R package “*Rsolnp*” (74). To ensure
723 optimality of the obtained solutions and avoid local minima, 10 random restarts were chosen
724 among 1000 uniformly-sampled input parameter sets and the optimization procedure was run
725 separately for each restart (implemented in function “*gosolnp*” in the same R package). To
726 capture the variance of the optimal intervention profile, since the output of a GP model is a
727 distribution, we solved the above optimization problem for several cases and we report the
728 distribution of the obtained minima when:

$$(i) \quad g(\mathbf{x}) = \mu$$

$$(ii) \quad g(\mathbf{x}) = \mu \pm \sigma$$

$$(iii) \quad g(\mathbf{x}) = \mu \pm 2\sigma$$

729 where μ is the predicted mean of the GP model and σ is the standard deviation. Where the
730 nonlinear optimization algorithm did not find any solutions, we performed an additional fine grid
731 search of 10000 uniformly-sampled data points.

732 In seasonal settings, at low transmission (simulated EIR < 2, corresponding simulated
733 true $PfPR_{2-10}$ < 11.7%), over 75% of simulations reached malaria elimination ($PfPR_{0-99} = 0$)
734 under the simulated levels of case management, before intervention deployment (Fig. S3.5). For
735 this reason, the space of obtained prevalence reductions following intervention deployment was

736 rather sparse and the obtained optima were not reliable and often did not converge. Therefore,
737 we chose to report minimum intervention profiles for settings with true $PfPR_{2-10} \geq 11.7\%$ (with
738 RDTs this yields a patent $PfPR_{2-10} \geq 5.8\%$).

739

740 **5 Iterative communication with stakeholders**

741 During the development of our methodological framework, we actively engaged in regular
742 communication and exchanges with different expert groups. The stakeholders involved in these
743 discussions were the Bill and Melinda Gates Foundation (BMGF), the Innovative Vector Control
744 Consortium (IVCC) and the PATH's Malaria Vaccine Initiative (PATH-MVI). Coordinated by
745 BMGF, these exchanges ensured a crucial discussion environment, aiding and guiding the
746 methodology at various levels: intervention profiling, and defining relevant intervention use
747 cases, and product characteristics. Furthermore, the framework has been presented and validated
748 in presence of the stakeholders in successive meetings. These discussions contributed towards
749 refining the investigation of various intervention profiles and led to exploration of intervention
750 combinations. Subsequently, the iterative exchanges with the stakeholders have not only shaped
751 but also proven the value of our methodological framework in its versatility to adapt addressing
752 relevant questions along the product development pathway.

753

754 **Acknowledgments:**

755 We would like to thank Lydia Burgert, Theresa Reiker, Andrew Shattock, Thomas Smith, and
756 Dylan Muir for insightful discussions and feedback on the developed methodology and the
757 manuscript. We would also like to thank Thomas van Boeckel and Amalio Telenti for providing
758 useful feedback on the manuscript. Calculations were performed at sciCORE
759 (<http://scicore.unibas.ch/>) scientific computing core facility at University of Basel. We would
760 further like to thank collaborators at the Innovative Vector Control Consortium (IVCC), PATH's
761 Malaria Vaccine Initiative (MVI) and Joerg Moehrle from Medicines for Malaria Venture
762 (MMV) for their insightful discussions and feedback on the model scenarios. This work has been
763 possible thanks to the Malaria Team at the Bill and Melinda Gates Foundation who facilitated
764 exchanges with the product development partners and supported model scenarios and
765 interpretations. In particular, we would like to thank Scott Miller, Jean-Luc Bodmer, Laura
766 Norris, Bruno Moonen, Dan Strickman, and Philip Welkhoff.

767 **Funding:** This work was supported by the Bill and Melinda Gates Foundation (OPP1170505 to
768 MAP) and the Swiss National Science Foundation (PP00P3_170702 to MAP);

769
770 **Author contributions:** M.G., G.Y. and M.A.P conceived the study, designed the simulation
771 experiments, developed methodology and analyzed the results. F.C., E.C., and N.C. provided
772 methodological expertise. E.M.S., N.H., M.M., and S.R contributed with their expertise
773 regarding product development, intervention properties and guided analysis. M.G., G.Y., M.A.P.
774 wrote the manuscript. All authors provided continuous feedback and approved the final
775 manuscript;

776
777 **Competing interests:** All authors declare no competing interests;

778
779 **Data and materials availability:** All the analysis code used in the paper as well as
780 corresponding documentation, parameterizations and configuration files for the software
781 workflow necessary to generate the simulation data with OpenMalaria and reproduce the analysis
782 are available at https://github.com/SwissTPH/TPP_workflow.

783
784
785 **Supplementary Materials are below following the references**

786 .
787 **List of Supplementary Figures and Tables**

788 The following supplementary Figures and Tables complement the analysis and results reported in
789 the main manuscript and are organized as follows:

- 790 • Description of the malaria disease transmission dynamics (OpenMalaria) model components
791 and assumptions:
 - 792 ○ **Table S1.1.** Overview of the OpenMalaria model components.
- 793 • Simulated malaria transmission dynamics in the presented analysis:
 - 794 ○ **Fig. S2.1.** Illustration of the yearly malaria transmission and prevalence patterns
795 in simulated seasonal settings.
 - 796 ○ **Fig. S2.2.** Simulated distributions of true and patent (detected with PCR or RDT)
797 $PfPR_{0-99}$ and $PfPR_{2-10}$ for various input EIR levels in absence of interventions.
- 798 • Parameterizations of simulated malaria interventions and their optimization setup:
 - 799 ○ **Fig. S2.3.** Representation of decay and the range of efficacy and half-life against
800 different parasite or vector targets for intervention-agnostic malaria interventions.
 - 801 ○ **Table S2.1.** Description and ranges of simulation variables.
 - 802 ○ **Table S2.2.** Specifications of the optimization procedure for TPP development.
- 803 • Simulation outputs:

- 804 ○ **Fig. S3.1.** Examples of OpenMalaria simulation outputs.
- 805 ○ **Fig. S3.2.** Distributions of prevalence reduction following yearly deployment of
- 806 single interventions.
- 807 ○ **Fig. S3.3.** Distributions of prevalence reduction following yearly deployment of
- 808 combinations of interventions.
- 809 ○ **Fig. S3.4.** Distributions of prevalence reduction following deployment of single
- 810 and combinations of interventions twice per year.
- 811 ○ **Fig. S3.5.** Simulations reaching malaria elimination before intervention
- 812 deployment.
- 813 ● Emulator training and evaluation:
 - 814 ○ **Fig. S4.1.** Assessment of the performance of the trained GP depending on the
 - 815 training set size.
 - 816 ○ **Fig. S4.2.** Performance of the trained GP emulators predicting immediate
 - 817 intervention impact.
 - 818 ○ **Fig. S4.3.** Performance of the trained GP emulators predicting long-term
 - 819 intervention impact.
 - 820 ○ **Table S4.1.** Performance of the trained Gaussian Process emulators predicting
 - 821 immediate and long-term intervention impact.
- 822 ● Summary of analysis results for all simulated transmission settings and interventions:
 - 823 ○ **Table S5.1.** Key findings guiding target product profiles of new malaria
 - 824 interventions.
- 825 ● Sensitivity analyses and impact determinants of interventions:
 - 826 ○ **Fig. S6.1.** Key drivers of impact for therapeutic malaria interventions across
 - 827 different transmission settings.
 - 828 ○ **Fig. S6.2.** Key drivers of impact for vector control malaria interventions across
 - 829 different transmission settings.
- 830 ● Feasible landscapes of optimal, constrained intervention profiles (TPPs) for achieving a
- 831 desired health goal across different transmission settings and operational factors:
 - 832 ○ **Fig. S7.1** Feasible landscapes of optimal, constrained intervention profiles (TPPs)
 - 833 for an anti-infective monoclonal antibody deployed once per year.
 - 834 ○ **Fig. S7.2.** Feasible landscapes of optimal, constrained intervention profiles
 - 835 (TPPs) for an anti-infective monoclonal antibody deployed twice per year.
 - 836 ○ **Fig. S7.3.** Feasible landscapes of optimal, constrained intervention profiles
 - 837 (TPPs) for an anti-infective vaccine deployed once per year.
 - 838 ○ **Fig. S7.4.** Feasible landscapes of optimal, constrained intervention profiles
 - 839 (TPPs) for a transmission-blocking vaccine deployed once per year.
 - 840 ○ **Fig. S7.5.** Feasible landscapes of optimal, constrained intervention profiles
 - 841 (TPPs) for attractive targeted sugar baits deployed once or twice per year.
 - 842 ○ **Fig. S7.6.** Feasible landscapes of optimal, constrained intervention profiles
 - 843 (TPPs) for eave tubes deployed once per year.
- 844 ● Minimum profiles of interventions for achieving a desired health goal across different
- 845 transmission settings and operational factors:
 - 846 ○ **Fig. S8.1.** Optimal intervention profiles (TPPs) for anti-infective monoclonal
 - 847 antibodies under various deployment regimes to achieve a $PfPR_{0-99}$ reduction of at
 - 848 least 70%.

- 849 ○ **Fig. S8.2.** Optimal intervention profiles (TPPs) for anti-infective vaccines under
850 various deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.
- 851 ○ **Fig. S8.3.** Optimal intervention profiles (TPPs) for transmission-blocking
852 vaccines under various deployment regimes to achieve a $PfPR_{0.99}$ reduction of at
853 least 70%.
- 854 ○ **Fig. S8.4.** Optimal intervention profiles (TPPs) for attractive targeted sugar baits
855 under various deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.
- 856 ○ **Fig. S8.5.** Optimal intervention profiles (TPPs) for eave tubes to achieve a $PfPR_{0.99}$
857 reduction of at least 70%.

858

859 **References and Notes:**

860

- 861 1. P. Cocco, A. Ayaz-Shah, M. P. Messenger, R. M. West, B. Shinkins, Target Product
862 Profiles for medical tests: a systematic review of current methods. *BMC medicine* **18**, 1-
863 12 (2020).
- 864 2. A. Brooks, J. K. Nunes, A. Garnett, R. Biellik, D. Leboulleux, A. J. Birkett, C. Loucq,
865 Aligning new interventions with developing country health systems: Target product
866 profiles, presentation, and clinical trial design. *Global Public Health* **7**, 931-945 (2012).
- 867 3. R. Chin, B. Y. Lee, *Principles and practice of clinical trial medicine*. (Elsevier, 2008).
- 868 4. J. N. Burrows, S. Duparc, W. E. Gutteridge, R. H. van Huijsduijnen, W. Kaszubska, F.
869 Macintyre, S. Mazzuri, J. J. Möhrle, T. N. Wells, New developments in anti-malarial
870 target candidate and product profiles. *Malaria journal* **16**, 26 (2017).
- 871 5. U. F. a. D. Administration., Guidance for industry and review staff Target Product Profile
872 — a strategic development process tool. available at
873 <https://www.fda.gov/media/102657/download>. (2007).
- 874 6. B. Y. Lee, D. S. Burke, Constructing target product profiles (TPPs) to help vaccines
875 overcome post-approval obstacles. *Vaccine* **28**, 2806-2809 (2010).
- 876 7. K. B. Ebels, C. Clerk, C. H. Crudder, S. McGray, K. Magnuson, K. Tietje, P. LaBarre, in
877 *IEEE Global Humanitarian Technology Conference (GHTC 2014)*. (IEEE, 2014), pp.
878 555-560.
- 879 8. H. Heesterbeek, R. M. Anderson, V. Andreasen, S. Bansal, D. De Angelis, C. Dye, K. T.
880 Eames, W. J. Edmunds, S. D. Frost, S. Funk, Modeling infectious disease dynamics in
881 the complex landscape of global health. *Science* **347**, (2015).
- 882 9. R. M. Anderson, B. Anderson, R. M. May, *Infectious diseases of humans: dynamics and*
883 *control*. (Oxford university press, 1991).
- 884 10. M. A. Penny, R. Verity, C. A. Bever, C. Sauboin, K. Galactionova, S. Flasche, M. T.
885 White, E. A. Wenger, N. Van de Velde, P. Pemberton-Ross, Public health impact and
886 cost-effectiveness of the RTS, S/AS01 malaria vaccine: a systematic comparison of
887 predictions from four mathematical models. *The Lancet* **387**, 367-375 (2016).
- 888 11. H. C. Slater, A. Ross, A. L. Ouédraogo, L. J. White, C. Nguon, P. G. Walker, P. Ngor, R.
889 Aguas, S. P. Silal, A. M. Dondorp, Assessing the impact of next-generation rapid
890 diagnostic tests on Plasmodium falciparum malaria elimination strategies. *Nature* **528**,
891 S94-S101 (2015).
- 892 12. J. Gerardin, C. A. Bever, B. Hamainza, J. M. Miller, P. A. Eckhoff, E. A. Wenger,
893 Optimal Population-Level Infection Detection Strategies for Malaria Control and

- 894 Elimination in a Spatial Model of Malaria Transmission. *PLOS Computational Biology*
895 **12**, e1004707 (2016).
- 896 13. M. Walker, J. I. Hamley, P. Milton, F. Monnot, B. Pedrique, M.-G. Basáñez, Designing
897 antifilarial drug trials using clinical trial simulators. *Nature Communications* **11**, 1-11
898 (2020).
- 899 14. H. Kimko, J. Pinheiro, Model-based clinical drug development in the past, present and
900 future: a commentary. *Br. J. Clin. Pharmacol.* **79**, 108-116 (2015).
- 901 15. C. Vegvari, E. Cauet, C. Hadjichrysanthou, E. Lawrence, G.-J. Weverling, F. De Wolf,
902 R. M. Anderson, Using clinical trial simulators to analyse the sources of variance in
903 clinical trials of novel therapies for acute viral infections. *PloS one* **11**, (2016).
- 904 16. P. Selvaraj, J. Suresh, E. A. Wenger, C. A. Bever, J. Gerardin, Reducing malaria burden
905 and accelerating elimination with long-lasting systemic insecticides: a modelling study of
906 three potential use cases. *Malaria journal* **18**, 307-307 (2019).
- 907 17. O. J. Brady, H. C. Slater, P. Pemberton-Ross, E. Wenger, R. J. Maude, A. C. Ghani, M.
908 A. Penny, J. Gerardin, L. J. White, N. Chitnis, Role of mass drug administration in
909 elimination of *Plasmodium falciparum* malaria: a consensus modelling study. *The Lancet*
910 *Global Health* **5**, e680-e687 (2017).
- 911 18. M. Kretzschmar, Disease modeling for public health: added value, challenges, and
912 institutional constraints. *Journal of public health policy* **41**, 39-51 (2020).
- 913 19. K. Panayidou, S. Gsteiger, M. Egger, G. Kilcher, M. Carreras, O. Efthimiou, T. P.
914 Debray, S. Trelle, N. Hummel, G. m. r. group, GetReal in mathematical modelling: a
915 review of studies predicting drug effectiveness in the real world. *Research synthesis*
916 *methods* **7**, 264-277 (2016).
- 917 20. L. Rychetnik, M. Frommer, P. Hawe, A. Shiell, Criteria for evaluating evidence on public
918 health interventions. *Journal of Epidemiology and Community Health* **56**, 119 (2002).
- 919 21. A. B. Hogan, P. Winskill, R. Verity, J. T. Griffin, A. C. Ghani, Modelling population-
920 level impact to inform target product profiles for childhood malaria vaccines. *BMC*
921 *medicine* **16**, 1-11 (2018).
- 922 22. G. F. Killeen, N. Chitnis, S. J. Moore, F. O. Okumu, Target product profile choices for
923 intra-domiciliary malaria vector control pesticide products: repel or kill? *Malaria journal*
924 **10**, 207 (2011).
- 925 23. W. Pan-Ngum, T. Kinyanjui, M. Kiti, S. Taylor, J.-F. Toussaint, S. Saralamba, T. Van
926 Effelterre, D. J. Nokes, L. J. White, Predicting the relative impacts of maternal and
927 neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus
928 modelling approach. *Vaccine* **35**, 403-409 (2017).
- 929 24. C. E. Rasmussen, C. K. I. Williams, *Gaussian Processes for Machine Learning (Adaptive*
930 *Computation and Machine Learning)*. (The MIT Press, 2005).
- 931 25. D. Ríos Insua, F. Ruggeri, M. P. Wiper, *Bayesian analysis of stochastic process models*.
932 (Wiley, Chichester, 2012).
- 933 26. WHO, World Health Organization: Global report on insecticide resistance in malaria
934 vectors: 2010–2016 accessed at
935 https://www.who.int/malaria/areas/vector_control/insecticide_resistance/en/. (2018).
- 936 27. L. J. Espinoza, Malaria Resurgence in the Americas: An Underestimated Threat.
937 *Pathogens* **8**, (2019).
- 938 28. C. J. M. Whitty, E. Ansah, Malaria control stalls in high incidence areas. *BMJ* **365**, l2216
939 (2019).

- 940 29. T. Smith, N. Maire, A. Ross, M. Penny, N. Chitnis, A. Schapira, A. Studer, B. Genton, C.
941 Lengeler, F. Tediosi, D. De Savigny, M. Tanner, Towards a comprehensive simulation
942 model of malaria epidemiology and control. *Parasitology* **135**, 1507-1516 (2008).
- 943 30. P. Winskill, P. G. T. Walker, J. T. Griffin, A. C. Ghani, Modelling the cost-effectiveness
944 of introducing the RTS,S malaria vaccine relative to scaling up other malaria
945 interventions in sub-Saharan Africa. *BMJ Global Health* **2**, e000090 (2017).
- 946 31. P. Winskill, P. G. Walker, R. E. Cibulskis, A. C. Ghani, Prioritizing the scale-up of
947 interventions for malaria control and elimination. *Malaria Journal* **18**, 122 (2019).
- 948 32. E. Korenromp, G. Mahiané, M. Hamilton, C. Pretorius, R. Cibulskis, J. Lauer, T. A.
949 Smith, O. J. T. Briët, Malaria intervention scale-up in Africa: effectiveness predictions
950 for health programme planning tools, based on dynamic transmission modelling. *Malaria*
951 *Journal* **15**, 417 (2016).
- 952 33. T. Smith, G. F. Killeen, N. Maire, A. Ross, L. Molineaux, F. Tediosi, G. Hutton, J.
953 Utzinger, K. Dietz, M. Tanner, Mathematical modeling of the impact of malaria vaccines
954 on the clinical epidemiology and natural history of Plasmodium falciparum malaria:
955 overview. *The American Journal of Tropical Medicine and Hygiene* **75**, 1-10 (2006).
- 956 34. E. Cameron, K. E. Battle, S. Bhatt, D. J. Weiss, D. Bisanzio, B. Mappin, U. Dalrymple,
957 S. I. Hay, D. L. Smith, J. T. Griffin, E. A. Wenger, P. A. Eckhoff, T. A. Smith, M. A.
958 Penny, P. W. Gething, Defining the relationship between infection prevalence and
959 clinical incidence of Plasmodium falciparum malaria. *Nature Communications* **6**, 8170
960 (2015).
- 961 35. C. E. Utazi, J. Thorley, V. A. Alegana, M. J. Ferrari, S. Takahashi, C. J. E. Metcalf, J.
962 Lessler, F. T. Cutts, A. J. Tatem, Mapping vaccination coverage to explore the effects of
963 delivery mechanisms and inform vaccination strategies. *Nature communications* **10**, 1-10
964 (2019).
- 965 36. A. L. Wilson, O. Courtenay, L. A. Kelly-Hope, T. W. Scott, W. Takken, S. J. Torr, S. W.
966 Lindsay, The importance of vector control for the control and elimination of vector-borne
967 diseases. *PLoS neglected tropical diseases* **14**, e0007831 (2020).
- 968 37. N. M. Ferguson, Challenges and opportunities in controlling mosquito-borne infections.
969 *Nature* **559**, 490-497 (2018).
- 970 38. J. Gutman, S. Kovacs, G. Dorsey, A. Stergachis, F. O. ter Kuile, Safety, tolerability, and
971 efficacy of repeated doses of dihydroartemisinin-piperazine for prevention and
972 treatment of malaria: a systematic review and meta-analysis. *The Lancet infectious*
973 *diseases* **17**, 184-193 (2017).
- 974 39. F. Macintyre, H. Ramachandrani, J. N. Burrows, R. Holm, A. Thomas, J. J. Möhrle, S.
975 Duparc, R. H. van Huijsduijnen, B. Greenwood, W. E. Gutteridge, Injectable anti-
976 malarials revisited: discovery and development of new agents to protect against malaria.
977 *Malaria journal* **17**, 402 (2018).
- 978 40. L. T. Wang, L. S. Pereira, Y. Flores-Garcia, J. O'Connor, B. J. Flynn, A. Schön, N. K.
979 Hurlburt, M. Dillon, A. S. Yang, A. Fabra-García, A Potent Anti-Malarial Human
980 Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes
981 Sporozoites in the Liver. *Immunity* **53**, 733-744. e738 (2020).
- 982 41. D. J. Weiss, T. C. Lucas, M. Nguyen, A. K. Nandi, D. Bisanzio, K. E. Battle, E.
983 Cameron, K. A. Twohig, D. A. Pfeffer, J. A. Rozier, Mapping the global prevalence,
984 incidence, and mortality of Plasmodium falciparum, 2000–17: a spatial and temporal
985 modelling study. *The Lancet* **394**, 322-331 (2019).

- 986 42. M. Sahu, F. Tediosi, A. M. Noor, J. J. Aponte, G. Fink, Health systems and global
987 progress towards malaria elimination, 2000–2016. *Malaria journal* **19**, 1-12 (2020).
- 988 43. R. Ristl, S. Urach, G. Rosenkranz, M. Posch, Methods for the analysis of multiple
989 endpoints in small populations: A review. *Journal of biopharmaceutical statistics* **29**, 1-
990 29 (2019).
- 991 44. Food, D. Administration, Multiple endpoints in clinical trials: guidance for industry.
992 *College Park, Maryland: Food and Drug Administration*, (2017).
- 993 45. T. Smith, A. Ross, N. Maire, N. Chitnis, A. Studer, D. Hardy, A. Brooks, M. Penny, M.
994 Tanner, Ensemble Modeling of the Likely Public Health Impact of a Pre-Erythrocytic
995 Malaria Vaccine. *PLOS Medicine* **9**, e1001157 (2012).
- 996 46. N. Chitnis, T. Smith, R. Steketee, A mathematical model for the dynamics of malaria in
997 mosquitoes feeding on a heterogeneous host population. *Journal of Biological Dynamics*
998 **2**, 259-285 (2008).
- 999 47. N. Chitnis, D. Hardy, T. Smith, A Periodically-Forced Mathematical Model for the
1000 Seasonal Dynamics of Malaria in Mosquitoes. *Bulletin of Mathematical Biology* **74**,
1001 1098-1124 (2012).
- 1002 48. N. Maire, T. Smith, A. Ross, S. Owusu-Agyei, K. Dietz, L. Molineaux, A model for
1003 natural immunity to asexual blood stages of *Plasmodium falciparum* malaria in endemic
1004 areas. *The American journal of tropical medicine and hygiene* **75**, 19-31 (2006).
- 1005 49. A. Ross, G. Killeen, T. Smith, Relationships between host infectivity to mosquitoes and
1006 asexual parasite density in *Plasmodium falciparum*. *The American journal of tropical*
1007 *medicine and hygiene* **75**, 32-37 (2006).
- 1008 50. A. Ross, N. Maire, L. Molineaux, T. Smith, An epidemiologic model of severe morbidity
1009 and mortality caused by *Plasmodium falciparum*. *The American journal of tropical*
1010 *medicine and hygiene* **75**, 63-73 (2006).
- 1011 51. T. Smith, A. Ross, N. Maire, C. Rogier, J.-F. Trape, L. Molineaux, An epidemiologic
1012 model of the incidence of acute illness in *Plasmodium falciparum* malaria. *The American*
1013 *journal of tropical medicine and hygiene* **75**, 56-62 (2006).
- 1014 52. F. Tediosi, N. Maire, T. Smith, G. Hutton, J. Utzinger, A. Ross, M. Tanner, An approach
1015 to model the costs and effects of case management of *plasmodium falciparum* malaria in
1016 sub-saharan Africa. *The American Journal of Tropical Medicine and Hygiene* **75**, 90-103
1017 (2006).
- 1018 53. M. A. Penny, N. Maire, C. A. Bever, P. Pemberton-Ross, O. J. T. Briët, D. L. Smith, P.
1019 W. Gething, T. A. Smith, Distribution of malaria exposure in endemic countries in Africa
1020 considering country levels of effective treatment. *Malaria Journal* **14**, 384 (2015).
- 1021 54. N. R. Smith, J. M. Trauer, M. Gambhir, J. S. Richards, R. J. Maude, J. M. Keith, J. A.
1022 Flegg, Agent-based models of malaria transmission: a systematic review. *Malaria journal*
1023 **17**, 1-16 (2018).
- 1024 55. T. Reiker, N. Chitnis, T. A. Smith, Modelling reactive case detection strategies for
1025 interrupting transmission of *Plasmodium falciparum* malaria. *Malaria Journal* **18**, 259
1026 (2019).
- 1027 56. N. Maire, F. Tediosi, A. Ross, T. Smith, Predictions of the epidemiologic impact of
1028 introducing a pre-erythrocytic vaccine into the expanded program on immunization in
1029 sub-Saharan Africa. *The American Journal of Tropical Medicine and Hygiene* **75**, 111-
1030 118 (2006).

- 1031 57. A. M. Ekström, J. Clark, P. Byass, A. Lopez, D. De Savigny, C. A. Moyer, H. Campbell,
1032 A. J. Gage, P. Bocquier, C. AbouZahr, O. Sankoh, INDEPTH Network: contributing to
1033 the data revolution. *The Lancet Diabetes & Endocrinology* **4**, 97 (2016).
- 1034 58. G. F. Killeen, A. Ross, T. Smith, Infectiousness of malaria-endemic human populations to
1035 vectors. *The American Journal of Tropical Medicine and Hygiene* **75**, 38-45 (2006).
- 1036 59. T. C. Smith, J. D. D. Charlwood, J. Kihonda, S. Mwankusye, P. F. Billingsley, J.
1037 Meuwissen, E. B. Lyimo, W. Takken, T. Teuscher, M. Tanner, Absence of seasonal
1038 variation in malaria parasitaemia in an area of intense seasonal transmission. *Acta tropica*
1039 **54** **1**, 55-72 (1993).
- 1040 60. C. Drakeley, D. Schellenberg, J. Kihonda, C. Sousa, A. Arez, D. Lopes, J. Lines, H.
1041 Mshinda, C. Lengeler, J. A. Schellenberg, An estimation of the entomological inoculation
1042 rate for Ifakara: a semi-urban area in a region of intense malaria transmission in
1043 Tanzania. *Tropical Medicine & International Health* **8**, 767-774 (2003).
- 1044 61. A. M. Shaukat, J. G. Breman, F. E. McKenzie, Using the entomological inoculation rate
1045 to assess the impact of vector control on malaria parasite transmission and elimination.
1046 *Malaria journal* **9**, 122 (2010).
- 1047 62. L. S. Tusting, T. Bousema, D. L. Smith, C. Drakeley, in *Advances in parasitology*.
1048 (Elsevier, 2014), vol. 84, pp. 151-208.
- 1049 63. M. Stein, Large Sample Properties of Simulations Using Latin Hypercube Sampling.
1050 *Technometrics* **29**, 143-151 (1987).
- 1051 64. M. Binois, R. B. Gramacy, M. Ludkovski, Practical heteroscedastic gaussian process
1052 modeling for large simulation experiments. *Journal of Computational and Graphical*
1053 *Statistics* **27**, 808-821 (2018).
- 1054 65. M. Binois, R. Gramacy, hetGP: Heteroskedastic Gaussian Process Modeling and Design
1055 under Replication. *R package version 1*, (2017).
- 1056 66. A. M. Gopakumar, P. V. Balachandran, D. Xue, J. E. Gubernatis, T. Lookman, Multi-
1057 objective optimization for materials discovery via adaptive design. *Scientific reports* **8**,
1058 3738 (2018).
- 1059 67. R. Dehghannasiri, D. Xue, P. V. Balachandran, M. R. Yousefi, L. A. Dalton, T.
1060 Lookman, E. R. Dougherty, Optimal experimental design for materials discovery.
1061 *Computational Materials Science* **129**, 311-322 (2017).
- 1062 68. M. Binois, J. Huang, R. B. Gramacy, M. Ludkovski, Replication or Exploration?
1063 Sequential Design for Stochastic Simulation Experiments. *Technometrics* **61**, 7-23
1064 (2019).
- 1065 69. I. M. Sobol', Global sensitivity indices for nonlinear mathematical models and their
1066 Monte Carlo estimates. *Mathematics and Computers in Simulation* **55**, 271-280 (2001).
- 1067 70. A. Saltelli, S. Tarantola, F. Campolongo, M. Ratto, *Sensitivity Analysis in Practice: A*
1068 *Guide to Assessing Scientific Models*. (Halsted Press, 2004).
- 1069 71. R. C. Team. (Vienna, Austria, 2013).
- 1070 72. M. R. Hestenes, Multiplier and gradient methods. *Journal of Optimization Theory and*
1071 *Applications* **4**, 303-320 (1969).
- 1072 73. Y. Ye, Ph. D. thesis, Department of ESS, Stanford University, (1987).
- 1073 74. A. Ghalanos, S. Theussl, Rsolnp: general non-linear optimization using augmented
1074 Lagrange multiplier method. *R package version 1*, (2012).
- 1075 75. T. Smith, N. Maire, K. Dietz, G. F. Killeen, P. Vounatsou, L. Molineaux, M. Tanner,
1076 Relationship between the entomologica inoculation rate and the force of infection for

- 1077 Plasmodium Falciparum malaria. *The American Journal of Tropical Medicine and*
1078 *Hygiene* **75**, 11-18 (2006).
- 1079 76. W. E. Collins, G. M. Jeffery, A retrospective examination of the patterns of
1080 recrudescence in patients infected with Plasmodium falciparum. *The American journal of*
1081 *tropical medicine and hygiene* **61**, 44-48 (1999).
- 1082 77. G. F. Killeen, A. Ross, T. Smith, Infectiousness of malaria-endemic human populations
1083 to vectors. *The American journal of tropical medicine and hygiene* **75**, 38-45 (2006).
- 1084 78. A. Ross, T. Smith, The effect of malaria transmission intensity on neonatal mortality in
1085 endemic areas. *The American journal of tropical medicine and hygiene* **75**, 74-81 (2006).
- 1086 79. E. M. Stuckey, T. Smith, N. Chitnis, Seasonally Dependent Relationships between
1087 Indicators of Malaria Transmission and Disease Provided by Mathematical Model
1088 Simulations. *PLOS Computational Biology* **10**, e1003812 (2014).
- 1089
1090
1091

1092 **Supplementary Materials:**

1093 **Title: Combining machine learning and mathematical models of disease**
1094 **dynamics to guide development of novel disease interventions**

1095 **Authors:** Monica Golumbeanu^{1,2†}, Guojing Yang^{1,2†}, Flavia Camponovo^{1,2,3}, Erin M. Stuckey⁴,
1096 Nicholas Hamon⁵, Mathias Mondy⁵, Sarah Rees⁵, Nakul Chitnis^{1,2}, Ewan Cameron^{6,7,8}, and
1097 Melissa A. Penny^{1,2*}

1098 **Affiliations:**

1099 ¹Swiss Tropical and Public Health Institute, Basel, Switzerland

1100 ²University of Basel, Basel, Switzerland

1101 ³Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T. H.
1102 Chan School of Public Health, Boston, MA 02115, USA

1103 ⁴The Bill and Melinda Gates Foundation, Seattle, WA, USA

1104 ⁵Innovative Vector Control Consortium, Liverpool, United Kingdom

1105 ⁶Malaria Atlas Project, Big Data Institute, University of Oxford, Oxford, UK

1106 ⁷Curtin University, Perth, Australia

1107 ⁸Telethon Kids Institute, Perth Children's Hospital, Perth, Australia

1108 *Correspondence to: melissa.penny@unibas.ch

1109 †These authors contributed equally.

1110 **One Sentence Summary:** Defining quantitative profiles of novel disease interventions by
1111 combining machine learning with mathematical models of disease transmission

1112 **Short title:** Quantitatively defining new disease interventions

1113

1114 **Supplementary Materials:**

1115

1116 **Table of contents**

1117	1 Disease model	41
1118	Table S1.1 Overview of the OpenMalaria model components.	42
1119	2 Disease scenarios	43
1120	Figure S2.1 Illustration of the yearly malaria transmission and prevalence patterns in simulated 1121 seasonal settings.	43
1122	Figure S2.2 Simulated distributions of true and patent (detected with PCR or RDT) <i>PfPR</i> ₀₋₉₉ and 1123 <i>PfPR</i> ₂₋₁₀ for various input EIR levels in absence of interventions.	45
1124	Figure S2.3 Representation of decay and the range of efficacy and half-life against different 1125 parasite or vector targets for intervention-agnostic malaria interventions.	46
1126	Table S2.1 Description and ranges of simulation variables.	47
1127	Table S2.2 Specifications of the optimization procedure for TPP development.	48
1128	3 Results: Disease model simulations	50
1129	Figure S3.1. Examples of OpenMalaria simulation outputs.	50
1130	Figure S3.2. Distributions of prevalence reduction following yearly deployment of single 1131 interventions.	51
1132	Figure S3.3. Distributions of prevalence reduction following yearly deployment of combinations 1133 of interventions.	52

1134	Figure S3.4. Distributions of prevalence reduction following deployment of single and	
1135	combinations of interventions twice per year.	53
1136	Figure S3.5. Simulations reaching malaria elimination before intervention deployment.....	54
1137	4 Results: Emulator performance	55
1138	Figure S4.1. Assessment of the performance of the trained GP depending on the training set	
1139	size.	55
1140	Figure S4.2. Performance of the trained GP emulators predicting immediate intervention impact.	
1141	56
1142	Figure S4.3. Performance of the trained GP emulators predicting long-term intervention impact.	
1143	57
1144	Table S4.1. Performance of the trained GP emulators predicting immediate and long-term	
1145	intervention impact.....	58
1146	5 Results: Summary of key intervention impact determinants, optimal intervention profiles, and	
1147	vaccine results	59
1148	Table S5.1. Key findings guiding target product profiles of new malaria interventions.	60
1149	6 Results: Key determinants of impact.....	61
1150	Figure S6.1. Key drivers of impact for therapeutic malaria interventions across different	
1151	transmission settings.....	61
1152	Figure S6.2. Key drivers of impact for vector control malaria interventions across different	
1153	transmission settings.....	63
1154	7 Results: Feasible landscapes of optimal, constrained intervention profiles	64
1155	Figure S7.1. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-	
1156	infective monoclonal antibody deployed once per year.	64
1157	Figure S7.2. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-	
1158	infective monoclonal antibody deployed twice per year.	66
1159	Figure S7.3 Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-	
1160	infective vaccine deployed once per year.	67
1161	Figure S7.4. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for a	
1162	transmission-blocking vaccine deployed once per year.	68
1163	Figure S7.5. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for	
1164	attractive targeted sugar baits deployed once or twice per year.	69
1165	Figure S7.6. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for eave	
1166	tubes deployed once per year.....	70
1167	8 Results: Optimal intervention profiles.....	71
1168	Figure S8.1 Optimal intervention profiles (TPPs) for anti-infective monoclonal antibodies under	
1169	various deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.	71
1170	Figure S8.2 Optimal intervention profiles (TPPs) for anti-infective vaccines under various	
1171	deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.....	72
1172	Figure S8.3 Optimal intervention profiles (TPPs) for transmission-blocking vaccines under	
1173	various deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.	73
1174	Figure S8.4 Optimal intervention profiles (TPPs) for attractive targeted sugar baits under various	
1175	deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.....	74
1176	Figure S8.5 Optimal intervention profiles (TPPs) for eave tubes to achieve a $PfPR_{0.99}$ reduction	
1177	of at least 70%.....	75
1178		
1179		

1180 **1 Disease model**
 1181
 1182

Name	Description and assumptions	References
Key modelled epidemiological processes		
Malaria infection of humans	<ul style="list-style-type: none"> - Determined by EIR which is a model input and affects the force of infection in the simulated setting - Exposure of humans to mosquitoes depends on age 	(33, 75)
Infection progression in humans: asexual parasite densities and immunity	<ul style="list-style-type: none"> - Blood stage parasite density depends on the time since infection and is affected by naturally acquired immunity - The duration of infection follows a log-normal distribution - Immunity (both pre-erythrocytic and blood-stage) develops progressively following consequent episodes of exposure to infection and decays exponentially - Acquired immunity reduces parasite density of subsequent infections - Super-infection is possible with cumulative parasite densities 	(33, 48, 75, 76)
Transmission from infected humans to mosquitoes	<ul style="list-style-type: none"> - Depends on the density of parasites present in the human with gametocyte densities following a lag from parasite densities 	(33, 49, 77)
Clinical illness, morbidity, mortality and anemia	<ul style="list-style-type: none"> - Acute clinical illness depends on human host parasite densities and their pyrogenic threshold which evolves over time depending on the individual exposure history - Acute morbidity episodes can be uncomplicated or evolve to severe episodes - A proposition of the severe episodes leads to deaths 	(33, 50, 51, 78)
Modelled characteristics of the transmission setting		
Population age structure	<ul style="list-style-type: none"> - Informed by health and demographic surveillance data from Tanzania 	(50, 57)
Transmission seasonality	<ul style="list-style-type: none"> - Seasonally-forced, the same transmission pattern is reproduced each year in absence of interventions 	(75, 79)
Case management	<ul style="list-style-type: none"> - Modelled through a comprehensive decision tree-based model which determines the corresponding treatment implications depending on the occurring clinical events such as fevers and seeking of care - Its representation includes specification of diagnostic tests, effects of treatment, case fatality, case sequelae and cure rates 	(52)
Entomological setting	<ul style="list-style-type: none"> - Comprehensive simulation of the mosquito lifecycle and behavior towards human and animal hosts (biting, resting) embedded in a dynamic entomological model of the mosquito oviposition cycle - Multiple vector species can be simulated simultaneously 	(47)

<u>Modelled interventions</u>	
Vector control	- Available interventions: long-lasting insecticide-treated nets (LLINs), indoor residual spraying (IRS), house screening, baited traps, repellents, push-pull
Drugs and Vaccines	- Drugs and vaccines acting at various levels of the parasite life cycle (transmission blocking, anti-infective, blood-stage clearance)
Deployment characteristics	- Interventions can be deployed for several rounds to a targeted group of individuals and specified coverages
<u>Simulation regimes and model variants</u>	
Time steps	- Simulation outputs are tracked every 5 days
Model variants	- Varying assumptions in immunity decay, treatment and heterogeneity of transmission result in 14 model variants (45)
<u>Software availability and documentation</u>	
	- Source code and wiki page available on GitHub: https://github.com/SwissTPH/openmalaria/


1183

1184 **Table S1.1**

1185 **Overview of the OpenMalaria model components.**

1186 The individual based stochastic model of malaria in humans and transmission has been described
1187 previously. This model was originally developed in 2003-2006 (33), with mosquito dynamics
1188 updated in 2008 (46) and an additional 13 structural model variants developed and parameterized
1189 in 2012 (45) representing different model assumptions on immunity decay, disease,
1190 comorbidities, and heterogeneity in transmission.
1191


1192 **2 Disease scenarios**
1193



1194


1195 **Figure S2.1**
1196 **Illustration of the yearly malaria transmission and prevalence patterns in simulated**
1197 **seasonal settings.**

1198 (A) Observed, normalized, monthly seasonal pattern of malaria EIR in Namawala, Tanzania
1199 extracted from (50). (B) Corresponding input, 5-day seasonal EIR pattern used in OpenMalaria
1200 simulations, obtained by scaling and extrapolating the monthly seasonality profile from (50) to 5-
1201 day time steps. For this example, the simulated input EIR was 7.78 infectious bites per person
1202 per year. (C) Resulting simulated yearly $PfPR_{0-99}$ profile. In all figures, the arrows indicate the
1203 month of September, the peak of transmission and show the delay between the peak of
1204 transmission and the resulting peak in malaria prevalence. The dotted vertical lines on figures
1205 (B) and (C) indicate the deployment times of first and second rounds of malaria interventions
1206 when applicable.
1207



1209 **Figure S2.2**
1210 **Simulated distributions of true and patent (detected with PCR or RDT) $PfPR_{0-99}$ and**
1211 **$PfPR_{2-10}$ for various input EIR levels in absence of interventions.**

1212 The input entomological inoculation rate (EIR) defines the simulated malaria transmission level.
1213 In every simulation experiment, EIR was uniformly sampled from the interval [1, 25]. In figures
1214 (A) – (C), each panel corresponds to a simulated setting and presents the distributions of true
1215 (A), patent with PCR (B) and patent with RDT (C) *Plasmodium falciparum* prevalence ($PfPR$,
1216 shown with boxplots, blue for 0-99 years old and orange for 2-10 years old) at varying EIR
1217 levels (x axis). The 6 represented settings are defined by the seasonality pattern (perennial shown
1218 in the first row, or seasonal shown in the second row of each figure) and mosquito indoor biting
1219 behavior (low- shown in the first column, mid- shown in the second column or high-indoor
1220 biting shown in the third column of each figure). Each EIR level on the x axis is defined as a set
1221 of continuous input EIR values which range between the current level and the current level - 1,
1222 e.g., an input EIR level of 1 contains EIR values in the interval (0, 1]. For each EIR level and
1223 setting, the case management levels, i.e., the probability of seeking care (access to treatment)
1224 within 5 days from the onset of fever (E_5), was varied within the interval [0.04 - 0.5]. PCR stands
1225 for polymerase chain reaction and RDT stands for rapid diagnostic test.
1226



1227

1228 **Figure S2.3**

1229 **Representation of decay and the range of efficacy and half-life against different parasite or**
1230 **vector targets for intervention-agnostic malaria interventions.**

1231 The simulated malaria interventions (A – F) were modeled in terms of their targets in the malaria
1232 transmission cycle. The effect of each intervention is represented through the half-life of its
1233 decay (x axis) as well as the initial efficacy (y axis). The color blocks represent the range of
1234 parameter space of efficacy and half-life of decay considered in the current analysis for each
1235 intervention. The half-life and the color block does not represent the entire duration of effect, as
1236 that depends on the decay shape chosen for each intervention. The decay shape for each
1237 intervention is displayed in the right side insert of each plot where the dotted lines specify the
1238 half-life and corresponding half of the intervention efficacy. The definitions of all the parameter
1239 ranges for all interventions are provided in each figure on the lower left side and detailed in
1240 Table S2.1.

1241

	Intervention	Coverage	Initial efficacy	Half-life or duration (years)	Decay type
Intervention profiles	<u>Prevent infection</u>				
	Anti-infective vaccine	0 - 1	0.3 - 0.95	0.5 - 5	Weibull (k = 0.8) (Sigmoidal)
	Anti-infective monoclonal antibody	0 - 1	0.3 - 0.95	0.167 - 0.667	Weibull (k = 3) (Biphasic)
	<u>Blood stage clearance</u>				
	Antimalarial drugs	0 - 1	0.8 - 1	0 - 0.1667	Exponential
	<u>Transmission blocking</u>				
	Vaccine	0 - 1	0.3 - 0.95	0.5 - 5	Weibull (k = 0.8) (Biphasic)
	<u>Preprandial killing effect (affects only indoor mosquito biting)</u>				
	Eave tubes	0 - 1	0.3 - 0.99	0.5 - 5	Weibull (k = 3) (Sigmoidal)
	<u>Preprandial and postprandial killing effect (affects indoor and outdoor mosquito biting)</u>				
	Attractive targeted sugar baits	0 - 1	0.7 - 0.99	0.167 – 0.667	Step
Transmission settings	<p><u>EIR range:</u> 1 – 25, representing a $PfPR_{0.99}$ of 13-88% and a $PfPR_{0.2}$ of 7.2-74%</p> <p><u>Case management (baseline scenario) range:</u> 0 – 0.8, corresponding to a probability of seeking care within 5 days from the onset of fever of 0-0.5</p> <p><u>Seasonality levels:</u></p> <ol style="list-style-type: none"> 1. high seasonal setting with one transmission peak over a year 2. perennial setting with constant yearly transmission <p><u>Proportion of indoor-biting mosquitoes, out of total indoor and outdoor biting mosquitoes:</u></p> <ol style="list-style-type: none"> 3. high (0.8) 4. medium (0.5) 5. low (0.2) 				

1242 **Table S2.1 Description and ranges of simulation variables.**

1243 Within each OpenMalaria simulation, the varied parameters and ranges correspond to the
1244 profiles of applied interventions (see Fig S2.3 for visual ranges of vector and parasite targets), as
1245 well as the transmission setting characteristics. The profile of each modeled malaria intervention
1246 is defined by its target, the ranges of the deployment coverage, initial efficacy, half-life or
1247 duration of effect as well the type of decay. Where interventions are applied to individual
1248 humans, in the present demonstrative analysis this is equally applied across ages, and not
1249 targeted to certain population. The transmission setting is defined by the yearly EIR, seasonality
1250 level, as well as proportion of indoor mosquitoes.


Intervention	Minimized profile	Intervention properties constraints	Specifications of combination therapies
Anti-infective monoclonal antibody (Sigmoidal decay)	Coverage	Coverage \in [0 .. 80%] Efficacy = 85% Half-life = 4 months	<u>Blood stage drug:</u> Efficacy = 90% Half-life = 10 days
	Efficacy	Coverage = 60% Efficacy \in [30% .. 95%] Half-life = 4 months	
	Half-life	Coverage = 60% Efficacy = 85% Half-life \in [2 .. 8 months]	
Anti-infective vaccine (Biphasic decay)	Coverage	Coverage \in [0 .. 80%] Efficacy = 85% Half-life = 7 months	<u>Blood stage drug:</u> Efficacy = 90% Half-life = 10 days
	Efficacy	Coverage = 60% Efficacy \in [30% .. 95%] Half-life = 7 months	
	Half-life	Coverage = 60% Efficacy = 85% Half-life \in [2 months .. 5 years]	
Transmission-blocking vaccine (Biphasic decay)	Coverage	Coverage \in [0 .. 80%] Efficacy = 85% Half-life = 7 months	<u>Blood stage drug:</u> Efficacy = 90% Half-life = 10 days
	Efficacy	Coverage = 60% Efficacy \in [30% .. 95%] Half-life = 7 months	
	Half-life	Coverage = 60% Efficacy = 85% Half-life \in [2 months .. 5 years]	
Attractive targeted sugar baits (Step decay)	Coverage	Coverage \in [0 .. 80%] Efficacy = 85% Half-life = 4 months	Not applicable
	Efficacy	Coverage = 60% Efficacy \in [70% .. 99%] Half-life = 4 months	
	Half-life	Coverage = 60% Efficacy = 85% Half-life \in [2 .. 8 months]	
Eave tubes (Sigmoidal decay)	Coverage	Coverage \in [0 .. 80%] Efficacy = 85% Half-life = 3 years	Not applicable
	Efficacy	Coverage = 60% Efficacy \in [30% .. 99%] Half-life = 3 years	
	Half-life	Coverage = 60% Efficacy = 85% Half-life \in [6 months .. 5 years]	

1251 **Table S2.2**
 1252 **Specifications of the optimization procedure for TPP development.**

1253 For each intervention, we successively identified the minimum profiles of the intervention
 1254 coverage, efficacy, and half-life. Precisely, we optimized each parameter separately (column
 1255 “Minimized profile”), according to its feasibility constraints while setting the two other

1256 parameters to the specified fixed values (column “Intervention properties constraints”). When
1257 deployed in combination with other drugs or vaccines, the additional interventions had fixed
1258 properties as well (column “Specifications of combination therapies”).
1259

1260 **3 Results: Disease model simulations**
1261




1262

1263 **Figure S3.1.**
1264 **Examples of OpenMalaria simulation outputs.**

1265 Time series of simulated malaria $PfPR_{0-99}$ in a perennial (A) and seasonal (B) setting. Both
1266 figures display the prevalence of malaria cases, $PfPR_{0-99}$, (y axis) across time (x axis).
1267 Interventions targeting different stages in the malaria transmission cycle (different colors) are
1268 applied once per year at the beginning of June (vertical dotted lines, in this example for three
1269 years of deployment). The effect of each intervention is assessed by evaluating the $PfPR_{0-99}$
1270 reduction in all ages relative to the year prior deployment (first grey block). Two outcomes are
1271 assessed, following an immediate and late follow-up (second and third grey blocks), depending
1272 on whether the average prevalence is calculated across the next year after deployment, or across
1273 the third year after deployment, respectively.
1274

1275



1276

1277

1278

1279

1280

1281

1282

1283

1284

1285

1286

1287

1288

1289


1290

1291

Figure S3.2.

Distributions of prevalence reduction following yearly deployment of single interventions.

Prevalence reduction was calculated by comparing the initial prevalence in the year before any interventions were deployed to the yearly prevalence obtained in the following year (short follow-up, panel **A**) and in the third year (long follow-up, panel **B**) after deployment of interventions. Each individual figure corresponds to a simulated setting and presents the distributions of $PfPR_{0-99}$ reduction (shown with boxplots) at varying EIR as well as corresponding simulated $PfPR_{2-10}$ levels (x axis). Each boxplot displays the interquartile range (box), the median value (horizontal line), the largest and smallest values within 1.5 times the interquartile range (whiskers), and the remaining outside values (points). The 6 represented settings in each panel are defined by the seasonality pattern (perennial or seasonal) and mosquito indoor biting behavior (low, mid or high indoor biting). Each EIR level on the x axis is defined as a set of continuous input EIR values which range between the current level and the current level - 1, e.g., an input EIR level of 1 contains all EIR values in the interval (0, 1]. The definitions and ranges of all the EIR levels is included in Table S2.1.



1292

1293

1294

1295

1296

1297

1298

1299

1300

1301

1302

1303

1304

1305

1306


1307

Figure S3.3.

Distributions of prevalence reduction following yearly deployment of combinations of interventions.


Prevalence reduction was calculated by comparing the initial prevalence in the year before any interventions were deployed to the yearly prevalence obtained in the following year (short follow-up, panel A) and in the third year (long follow-up, panel B) after deployment of interventions. Each individual figure corresponds to a simulated setting and presents the distributions of $PfPR_{0-99}$ reduction (shown with boxplots) at varying EIR as well as the corresponding simulated $PfPR_{2-10}$ levels (x axis). Each boxplot displays the interquartile range (box), the median value (horizontal line), the largest and smallest values within 1.5 times the interquartile range (whiskers), and the remaining outside values (points). The 6 represented settings in each panel are defined by the seasonality pattern (perennial or seasonal) and mosquito indoor biting behavior (low, mid or high indoor biting). Each EIR level on the x axis is defined as a set of continuous input EIR values which range between the current level and the current level - 1, e.g., an input EIR level of 1 contains EIR values in the interval (0, 1]. The definitions

1308 and ranges of all the EIR levels are included in Table S2.1. MDA stands for mass drug
 1309 administration.



1310
 1311 **Figure S3.4.**
 1312 **Distributions of prevalence reduction following deployment of single and combinations of**
 1313 **interventions twice per year.**
 1314 Prevalence reduction was calculated by comparing the initial prevalence in the year before any
 1315 interventions were deployed to the yearly prevalence obtained in the following year (short
 1316 follow-up, panel **A**) and in the third year (long follow-up, panel **B**) after deployment of
 1317 interventions. Each individual figure corresponds to a simulated setting and presents the
 1318 distributions of $PfPR_{0-99}$ reduction (shown with boxplots) at varying EIR as well as
 1319 corresponding simulated $PfPR_{2-10}$ levels (x axis). Each boxplot displays the interquartile range
 1320 (box), the median value (horizontal line), the largest and smallest values within 1.5 times the
 1321 interquartile range (whiskers), and the remaining outside values (points). The 6 represented
 1322 settings in each panel are defined by the seasonality pattern (perennial or seasonal) and mosquito
 1323 indoor biting behavior (low, mid or high indoor biting). Each EIR level on the x axis is defined
 1324 as a set of continuous input EIR values which range between the current level and the current

1325 level - 1, e.g., an input EIR level of 1 contains EIR values in the interval (0, 1]. The definitions
1326 and ranges of all the EIR levels for all simulated settings is included in Table S2.1. MDA stands
1327 for mass drug administration.



1328

1329 **Figure S3.5.**


1330 **Simulations reaching malaria elimination before intervention deployment.**

1331 The violin plots and boxplots in each panel present the distributions of the percentage of
1332 simulations reaching malaria elimination ($PfPR_{0-99} = 0$) before intervention deployment (this can
1333 arrive due to case management and only occurs in seasonal settings), across all simulated
1334 interventions and intervention combinations.

1335

1336
1337


4 Results: Emulator performance



1338
1339

1340 **Figure S4.1.**
1341 **Assessment of the performance of the trained GP depending on the training set size.**

1342 Each figure presents the Pearson correlation coefficient r^2 between true and predicted values on a
1343 broad range of out-of-sample test sets of varying length, when simulating deployment of an anti-
1344 infective monoclonal antibody deployed once per year (A) or twice per year (B) as well as in
1345 combination with a blood-stage drug once (C) or twice per year (D).
1346



1347

1348

Figure S4.2.

1349

Performance of the trained GP emulators predicting immediate intervention impact.

1350

For a wide range of deployed interventions and transmission settings (see Materials and

1351

Methods), GP emulators were trained to predict the immediate impact of each intervention, i.e.,

1352

the resulting average $PfPR_{0-99}$ reduction in the year following deployment of the intervention.

1353

The performance of the trained emulators was assessed by inspecting the Pearson correlation

1354

coefficient (r^2) and the mean squared error between true and predicted values on an out-of-

1355

sample test set. Figures (A) – (K) display the true and predicted values of each trained emulator

1356

across all deployed interventions in a seasonal transmission setting with high indoor biting.

1357


Figure (L) summarizes r^2 and the mean squared error of all the trained emulators for all

1358

simulated transmission settings and interventions (the simulated settings were defined by

1359

seasonality and mosquito biting patterns, see Table S2.1 for detailed values per setting).



1360

1361

Figure S4.3.

1362

Performance of the trained GP emulators predicting long-term intervention impact.

1363

1364

1365

1366

1367

1368

1369

1370

1371

1372

For a wide range of deployed interventions and transmission settings (see Methods), GP emulators were trained to predict the immediate impact of each intervention, i.e., the resulting average $PfPR_{0-99}$ reduction in the third year following deployment of the intervention. The performance of the trained emulators was assessed by inspecting the Pearson correlation coefficient (r^2) and the mean squared error between true and predicted values on an out-of-sample test set. Figures (A) – (K) display the true and predicted values of each trained emulator across all deployed interventions in a seasonal transmission setting with high indoor biting. Figure (L) summarizes r^2 and the mean squared error of all the trained emulators for all simulated transmission settings and interventions (the simulated settings were defined by seasonality and mosquito biting patterns, see Table S2.1 for detailed values per setting).

Intervention(s) (deployment)	Training set size	Test set size	Cross-validation r^2 and (mean error)	Test set r^2 and (mean error)
Anti-infective monoclonal antibody (once/year)	10000	5000	Immediate: 0.99 (1.02%) Long: 0.96 (1.15%)	Immediate: 0.99 (0.63%) Long: 0.97 (0.68%)
Anti-infective monoclonal antibody (twice/year)	5000	2500	Immediate: 0.99 (1.11%) Long: 0.97 (1.32%)	Immediate: 0.99 (0.91%) Long: 0.99 (0.83%)
Anti-infective monoclonal antibody + Blood stage drug (once/year)	10000	5000	Immediate: 0.99 (1.34%) Long: 0.96 (1.74%)	Immediate: 0.99 (1.18%) Long: 0.98 (1.05%)
Anti-infective monoclonal antibody + Blood stage drug (twice/year)	5000	2500	Immediate: 0.99 (1.26%) Long: 0.97 (1.98%)	Immediate: 0.99 (0.98%) Long: 0.99 (1.12%)
Anti-infective vaccine (once/year)	10000	5000	Immediate: 0.99 (1.08%) Long: 0.99 (1.3%)	Immediate: 0.99 (0.99%) Long: 0.99 (1.16%)
Anti-infective vaccine + Blood stage drug (once/year)	5000	2500	Immediate: 0.99 (1.18%) Long: 0.99 (1.63%)	Immediate: 0.99 (1.57%) Long: 0.99 (2.25%)
Transmission-blocking vaccine (once/year)	10000	5000	Immediate: 0.99 (1.13) Long: 0.99 (1.25%)	Immediate: 0.99 (0.89%) Long: 0.99 (1.07%)
Transmission-blocking vaccine + Blood stage drug (once/year)	5000	2500	Immediate: 0.99 (1.25%) Long: 0.99 (1.53%)	Immediate: 0.99 (1.68%) Long: 0.99 (2.23 %)
Attractive targeted sugar baits (once/year)	5000	2500	Immediate: 0.99 (1.26%) Long: 0.98 (1.71%)	Immediate: 0.99 (1.98%) Long: 0.99 (1.19%)
Attractive targeted sugar baits (twice/year)	5000	2500	Immediate: 0.99 (1.09%) Long: 0.99 (1.98%)	Immediate: 0.99 (1.03%) Long: 0.99 (1.29%)
Eave tubes (once/year)	10000	5000	Immediate: 0.99 (1.11%) Long: 0.99 (1.3%)	Immediate: 0.99 (0.89%) Long: 0.99 (1.26%)

1373 **Table S4.1.**
 1374 **Performance of the trained GP emulators predicting immediate and long-term intervention**
 1375 **impact.**

1376 For each modelled transmission setting defined by case management level and mosquito biting
 1377 patterns and for each intervention (Table S2.1), a comprehensive set of simulation scenarios was
 1378 built by sampling uniformly the parameter space (defined in Table S2.1) and simulation with
 1379 OpenMalaria. In this manner, a training and a test set were constructed. The training set was used
 1380 to train, for each setting and intervention, a Heteroskedastic GP model in a 5-fold cross-
 1381 validation procedure. The performance of the trained GP was assessed by computing the Pearson
 1382 correlation coefficient r^2 as well as the mean error between the true and predicted outcomes on
 1383 both out-of-sample cross-validation and test sets. For each intervention and follow-up
 1384 (immediate or long-term), the average r^2 and mean error for all the GP models trained across 6
 1385 settings (seasonal or perennial, high, medium or low mosquito indoor biting) are reported.

1386 **5 Results: Summary of key intervention impact determinants, optimal intervention**
 1387 **profiles, and vaccine results**
 1388

Intervention	Summary of analysis results	Relevant figures
<p>Therapeutic interventions</p> <ul style="list-style-type: none"> - Anti-infective monoclonal antibodies - Anti-infective vaccines - Transmission-blocking vaccines 	<p>Key determinants of impact</p> <ul style="list-style-type: none"> - The main driver of intervention impact was coverage - The second determinant of intervention impact depended on intervention half-life. For interventions with short half-lives such as monoclonal antibodies, the half-life was the second driver, while for long-term interventions such as vaccines, efficacy played a key role. - As opposed to long-term vaccines whose impact is mainly driven by coverage and efficacy, interventions with short half-life (e.g., anti-infective monoclonal antibodies) rely on the case management to prevent resurgence - The various biting patterns of mosquitoes did not influence the intervention determinants of impact 	<p>S6.1 and Figure 2</p>
	<p>Optimal intervention profiles</p> <ul style="list-style-type: none"> - As opposed to vaccines, anti-infective monoclonal antibodies require high efficacy and deployment coverage while achieving limited reduction in $PfPR_{0-99}$ with very little impact in perennial settings - Increasing the deployment frequency for anti-infective monoclonal antibodies from once to twice per year, extended the landscape of feasible health targets but mainly in seasonal settings - Combination with a blood-stage drug proved more impactful as compared to increasing the deployment frequency for anti-infective monoclonal antibodies, extending the achievable health goals in perennial settings as well 	<p>S7.1-S7.4 S8.1-S8.3 and Figure 3</p>
<p>Vector control interventions</p> <ul style="list-style-type: none"> - Attractive targeted sugar baits - Eave tubes 	<p>Key determinants of impact</p> <ul style="list-style-type: none"> - As with short-term therapeutic interventions such as anti-infective monoclonal antibodies, attractive targeted sugar baits rely on case management for preventing resurgence - We see limited difference between key drivers for attractive targeted sugar baits in different biting settings because mosquitoes sugar feed before indoor or outdoor biting. In contrast, we observe that intervention properties of eave tubes rather than health system access to treatment are larger drivers of impact in indoor biting settings, as mosquitoes in those 	<p>S6.2 and Figure 2</p>

	settings will be more likely to contact the eave tube.	
	Optimal intervention profiles <ul style="list-style-type: none">- Increasing deployment frequency from once to twice per year for attractive targeted sugar baits, resulted in a significant increase in intervention impact and less requirements in terms of coverage and half-life- Increasing efficacy of attractive targeted sugar baits did not have a significant impact	S7.5-S7.6 S8.4-S8.55 and Figure 3

1389

1390 **Table S5.1.**


1391 **Key findings guiding target product profiles of new malaria interventions.**

1392 A summary of key results concerning impact determinants and minimal intervention profiles as
1393 well as references to the corresponding illustrative figures is provided.

1394


1395

1396 **6 Results: Key determinants of impact**



1397
 1398 **Figure S6.1.**
 1399 **Key drivers of impact for therapeutic malaria interventions across different transmission**
 1400 **settings.**
 1401 Results of sensitivity analysis identifying the determinants of intervention impact on $PfPR_{0-99}$
 1402 reduction for anti-infective monoclonal antibodies (**A, B**), anti-infective vaccines (**C, D**) and
 1403 transmission-blocking vaccines (**E, F**). The distinct colors represent proportions of the GP
 1404 emulator output variance (relative importance) attributable to intervention efficacy, half-life,
 1405 deployment coverage, as well as health system access. Determinants of impact are shown for
 1406 both immediate and late follow-up, when interventions are applied once per year for three years
 1407 in different transmission settings (see full intervention specifications in the Methods section).
 1408 The transmission settings are defined by two seasonal settings (seasonal and perennial) and three
 1409 types of mosquito biting patterns (low, medium and high indoor biting). The mosquito biting
 1410 patterns had little to no effect on the results of the sensitivity analysis for these therapeutic

1411 interventions (see results for all settings for monoclonal antibodies in figures A and B).
1412 Therefore, only the results for seasonal and perennial settings with high indoor mosquito biting
1413 are displayed for the vaccine interventions.



1414

1415

1416

1417

1418

1419

1420

1421

1422

1423

1424

1425

1426

1427

1428

1429

1430

1431

1432


Figure S6.2.

Key drivers of impact for vector control malaria interventions across different transmission settings.

Results of sensitivity analysis identifying the determinants of intervention impact on $PfPR_{0-99}$ reduction for attractive targeted sugar baits (A, B) and eave tubes (C, D). The distinct colors represent proportions of the GP emulator output variance (relative importance) attributable to intervention efficacy, half-life, deployment coverage, as well as health system access. Determinants of impact are shown for both immediate and late follow-up, when interventions are applied once per year for three years in different transmission settings (see full intervention specifications in the Methods section). The transmission settings are defined by two seasonal settings (seasonal and perennial) and three types of mosquito biting patterns (low, medium and high indoor biting). Like for the therapeutic interventions in the previous figure, we see limited difference between key drivers for attractive targeted sugar baits in different biting settings as mosquitoes sugar feed before indoor or outdoor biting. In contrast, we observe that intervention properties of eave tubes rather than health system access to treatment are larger drivers of impact in indoor biting settings, as mosquitoes in those settings will be more likely to contact the eave tube.

1433

7 Results: Feasible landscapes of optimal, constrained intervention profiles



1434

1435

1436

1437

Figure S7.1. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-infective monoclonal antibody deployed once per year.

1438

1439

1440

1441

1442

1443


1444

1445

The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified by minimal reduction in $PfPR_{0-99}$, y axis) across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each intervention characteristic was minimized in turn, while keeping the other characteristics fixed (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for an anti-infective monoclonal antibody delivered alone and assessing immediate (A) and late (B) follow up, as well as when delivered in combination with a blood stage drug assessing immediate

1446 (C) and late (D) follow-up. The simulated case management level (E_5) for all the displayed
1447 optimization analyses was assumed 25%.

1448



1449

1450

Figure S7.2.

1451

Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-infective monoclonal antibody deployed twice per year.

1452

1453

The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified by minimal reduction in $PfPR_{0.99}$, y axis) across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each intervention characteristic was minimized in turn, while keeping the other characteristics fixed (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for an anti-infective monoclonal antibody delivered alone and assessing immediate (A) and late (B) follow up, as well as when delivered in combination with a blood stage drug assessing immediate (C) and late (D) follow-up. The simulated case management level (E_5) for all the displayed optimization analyses was assumed 25%.

1454

1455

1456

1457


1458

1459

1460

1461

1462



1463

1464

Figure S7.3

1465

Feasible landscapes of optimal, constrained intervention profiles (TPPs) for an anti-infective vaccine deployed once per year.

1466

1467

1468

1469

1470

1471

1472


1473

1474

1475

1476

The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified by minimal reduction in $PfPR_{0.99}$, y axis) across different late simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each intervention characteristic was minimized in turn, while keeping the other characteristics fixed (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for an anti-infective vaccine delivered alone and assessing immediate (A) and late (B) follow up, as well as when delivered in combination with a blood stage drug assessing immediate (C) and late (D) follow-up. The simulated case management level (E_5) for all the displayed optimization analyses was assumed 25%.




1477

1478

1479 **Figure S7.4. Feasible landscapes of optimal, constrained intervention profiles (TPPs) for a transmission-**
 1480 **blocking vaccine deployed once per year.**

1481 The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles
 1482 (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified
 1483 by minimal reduction in $PfPR_{0-99}$, y axis) across different simulated true $PfPR_{2-10}$ settings
 1484 (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each
 1485 intervention characteristic was minimized in turn, while keeping the other characteristics fixed
 1486 (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for
 1487 a transmission-blocking vaccine delivered alone and assessing immediate (A) and late (B) follow
 1488 up, as well as when delivered in combination with a blood stage drug assessing immediate (C)
 1489 and late (D) follow-up. The simulated case management level (E_5) for all the displayed
 1490 optimization analyses was assumed 25%.




1491

1492 **Figure S7.5.**

1493 **Feasible landscapes of optimal, constrained intervention profiles (TPPs) for attractive**
 1494 **targeted sugar baits deployed once or twice per year.**

1495 The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles
 1496 (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified
 1497 by minimal reduction in $PfPR_{0-99}$, y axis) across different simulated true $PfPR_{2-10}$ settings
 1498 (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each
 1499 intervention characteristic was minimized in turn, while keeping the other characteristics fixed
 1500 (fixed parameter values for each optimization are specified in Table S2.2). Results are shown for
 1501 attractive targeted sugar baits delivered alone once per year and assessing immediate (A) and late
 1502 (B) follow up, as well as when delivered twice per year assessing immediate (C) and late (D)
 1503 follow-up. The simulated case management level (E_5) for all the displayed optimization analyses
 1504 was assumed 25%.

1505




1506

1507 **Figure S7.6.**
 1508 **Feasible landscapes of optimal, constrained intervention profiles (TPPs) for eave tubes**
 1509 **deployed once per year.**

1510 The heatmaps represent landscapes of optimal, constrained intervention characteristic profiles
 1511 (minimum coverage, efficacy, and half-life) required to achieve various health goals (quantified
 1512 by minimal reduction in $PfPR_{0-99}$, y axis) across different simulated true $PfPR_{2-10}$ settings
 1513 (rounded values, x axis) with seasonal or perennial transmission and high indoor mosquito biting
 1514 (results for other biting patterns not shown as they are similar). Each intervention characteristic
 1515 was minimized in turn, while keeping the other characteristics fixed (fixed parameter values for
 1516 each optimization are specified in Table S2.2). Results are shown for eave tubes delivered alone
 1517 and assessing immediate (A) and late (B) follow up. The simulated case management level (E_5)
 1518 for all the displayed optimization analyses was assumed 25%.

1519

1520 **8 Results: Optimal intervention profiles**
 1521




1522

1523 **Figure S8.1**
 1524 **Optimal intervention profiles (TPPs) for anti-infective monoclonal antibodies under**
 1525 **various deployment regimes to achieve a $PfPR_{0-99}$ reduction of at least 70%.**

1526 Each figure displays minimum, constrained intervention characteristic profiles (minimum
 1527 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0-99}$ of
 1528 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal
 1529 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in
 1530 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization
 1531 are specified in Table S2.2). Results are shown when assessing $PfPR_{0-99}$ reduction at immediate
 1532 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the
 1533 displayed optimization analyses was assumed 25%.

1534



1535

1536

Figure S8.2

1537

Optimal intervention profiles (TPPs) for anti-infective vaccines under various deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.

1538

1539

1540

1541

1542

1543


1544

1545

1546

1547

Each figure displays minimum, constrained intervention characteristic profiles (minimum coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0.99}$ of 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal transmission and high indoor mosquito biting. Each intervention characteristic was minimized in turn, while keeping the other characteristics fixed (fixed parameter values for each optimization are specified in Table S2.2). Results are shown when assessing $PfPR_{0.99}$ reduction at immediate (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the displayed optimization analyses was assumed 25%.




1548

1549 **Figure S8.3**
 1550 **Optimal intervention profiles (TPPs) for transmission-blocking vaccines under various**
 1551 **deployment regimes to achieve a $PfPR_{0.99}$ reduction of at least 70%.**

1552 Each figure displays minimum, constrained intervention characteristic profiles (minimum
 1553 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0.99}$ of
 1554 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal
 1555 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in
 1556 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization
 1557 are specified in Table S2.2). Results are shown when assessing $PfPR_{0.99}$ reduction at immediate
 1558 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the
 1559 displayed optimization analyses was assumed 25%.

1560

1561




1562

1563 **Figure S8.4**
 1564 **Optimal intervention profiles (TPPs) for attractive targeted sugar baits under various**
 1565 **deployment regimes to achieve a $PfPR_{0-99}$ reduction of at least 70%.**

1566 Each figure displays minimum, constrained intervention characteristic profiles (minimum
 1567 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0-99}$ of
 1568 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal
 1569 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in
 1570 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization
 1571 are specified in Table S2.2). Results are shown when assessing $PfPR_{0-99}$ reduction at immediate
 1572 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the
 1573 displayed optimization analyses was assumed 25%.

1574

1575



1576

1577 **Figure S8.5**
 1578 **Optimal intervention profiles (TPPs) for eave tubes to achieve a $PfPR_{0.99}$ reduction of at**
 1579 **least 70%.**

1580 Each figure displays minimum, constrained intervention characteristic profiles (minimum
 1581 coverage, efficacy, and half-life, y axis) required to achieve a minimal reduction in $PfPR_{0.99}$ of
 1582 70% across different simulated true $PfPR_{2-10}$ settings (rounded values, x axis) with seasonal
 1583 transmission and high indoor mosquito biting. Each intervention characteristic was minimized in
 1584 turn, while keeping the other characteristics fixed (fixed parameter values for each optimization
 1585 are specified in Table S2.2). Results are shown when assessing $PfPR_{0.99}$ reduction at immediate
 1586 (A - C) and late (D - F) follow up. The simulated case management level (E_5) for all the
 1587 displayed optimization analyses was assumed 25%.

1588

1589